Výsledky vyhledávání - "апиксабан"

Zdroj: Drug development & registration; Том 13, № 1 (2024); 224-240 ; Разработка и регистрация лекарственных средств; Том 13, № 1 (2024); 224-240 ; 2658-5049 ; 2305-2066

Témata: фармакокинетика, DOAC, apixaban, HPLC-MS/MS, validation, COVID-19, pharmacokinetics, НОАК, апиксабан, ВЭЖХ-МС/МС, валидация

Popis souboru: application/pdf

Relation: https://www.pharmjournal.ru/jour/article/view/1759/1254; https://www.pharmjournal.ru/jour/article/view/1759/1300; https://www.pharmjournal.ru/jour/article/downloadSuppFile/1759/2135; Воробьева Н. М., Ткачева О. Н. Антикоагулянтная терапия у пожилых пациентов: дилемма выбора между эффективностью и безопасностью. Медицинский алфавит. 2018;2(16):6–14.; Панченко Е. П. Антитромботическая терапия ишемической болезни сердца: основы, проверенные временем. Терапевтический архив. 2019;91(6):19–24. DOI:10.26442/00403660.2019.06.000296.; Бокарев И. Н., Кондратьева Т. Б. Новые оральные антикоагулянты в клинической практике. Эффективность и проблемы. Клиническая медицина. 2016;94(5):383–387. DOI:10.18821/0023-2149-2016-94-5-383-387.; Van Rein N., Heide-Jørgensen U., Lijfering W. M., Dekkers O. M., Sørensen H. T., Cannegieter S. C. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy: results from a Nationwide Danish Cohort Study. Circulation. 2019;139(6):775–786. DOI:10.1161/CIRCULATIONAHA.118.036248.; Cools F., Wollaert B., Vervoort G., Verstraete S., Voet J., Hermans K., Heyse A., De Wolf A., Hollanders G., Boussy T., Anné W., Vercammen J., Faes D., Beutels M., Mairesse G., Purnode Ph., Blankoff I., Vandergoten P., Capiau L., Allu J., Bassand J., Kayani G. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. Acta Cardiologica. 2018;74(4):309–318. DOI:10.1080/00015385.2018.1494089.; Мелехов А. В., Гендлин Г. Е., Дадашова Э. Ф., Алексеева Е. М., Заиграев И. А., Никитин И. Г. Динамика применения антитромботических препаратов у больных с фибрилляцией предсердий: собственные данные и обзор отечественных регистров. Российский медицинский журнал.2017;23(3):116–126. DOI:10.18821/0869-2106-2017-23-3-116-126.; Груздева А. А., Хохлов А. Л., Ильин М. В. Оральные антикоагулянты в профилактике тромоэмболических осложнений у кардиологических пациентов: анализ применения в Российской Федерации. Качественная клиническая практика. 2020;1:69–79. DOI:10.37489/2588-0519-2020-1-69-79.; Колбин А. С., Касимова А. Р., Гиляревский С. Р. Сравнительный фармакоэкономический анализ применения апиксабана, ривароксабана и дабигатрана для профилактики развития инсульта и эмболий в сосуды большого круга кровообращения у пациентов с неклапанной фибрилляцией предсердий. Качественная клиническая практика. 2022;4:50–59. DOI:10.37489/2588-0519-2022-4-50-59.; Dzudovic J., Sakac M. C., Antunovic M., Repic A., Obradovic S., Djordjevic S., Dzudovic B. Development and validation of LC-MS/MS method for determination of plasma apixaban. Acta Chromatographica. 2022;34(3):332–337. DOI:10.1556/1326.2021.00948.; Levi M., Thachil J., Iba T., Levy J. H. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7:e438–e440. DOI:10.1016/S2352-3026(20)30145-9.; Wenzler E., Engineer M. H., Yaqoob M., Benken S. T. Safety and efficacy of apixaban for therapeutic anticoagulation in critically Ill ICU patients with severe COVID-19 respiratory disease. TH Open: Companion Journal to Thrombosis and Haemostasis. 2020;4(04):e376–e382. DOI:10.1055/s-0040-1720962.; Billett H. H., Reyes-Gil M., Szymanski J., Ikemura K., Stahl L. R., Lo Y., Rahman S., Gonzalez-Lugo J. D., Kushnir M., Barouqa M., Golestaneh L., Bellin E. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thrombosis and haemostasis. 2020;120(12):1691–1699. DOI:10.1055/s-0040-1720978.; Appiah D., Quinn N. J., Messing E. G., Veltri K. T. Safety and efficacy analysis of apixaban compared to heparins in hospitalized non-critically ill COVID-19 patients. Hospital Pharmacy. 2022;57(6):727–733. DOI:10.1177/00185787221095764.; Pinto D. J., Orwat M. J., Koch S., Rossi K. A., Alexander R. S., Smallwood A., Wong P. C., Rendina A. R., Luettgen J. M., Knabb R. M., He K., Xin B., Wexler R. R., Lam P. Y. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Journal of medicinal chemistry. 2007;50(22):5339–5356. DOI:10.1021/jm070245n.; Luettgen J. M., Knabb R. M., He K., Pinto D. J., Rendina A. R. Apixaban inhibition of factor Xa: microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. Journal of Enzyme Inhibition and Medicinal Chemistry. 2011;26(4):514–526. DOI:10.3109/14756366.2010.535793.; Byon W., Garonzik S., Boyd R. A., Frost C. E. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clinical pharmacokinetics. 2019;58(10):1265–1279. DOI:10.1007/s40262-019-00775-z.; Granger C. B, Alexander J. H, McMurray J. J. V, Lopes R. D., Hylek E. M., Hanna M., Al-Khalidi H. R., Ansell J., Atar D., Avezum A., Bahit M. C., Diaz R., Easton J. D., Ezekowitz J. A., Flaker G., Garcia D., Geraldes M., Gersh B. J., Golitsyn S., Goto S., Hermosillo A. G., Hohnloser S. H., Horowitz J., Mohan P., Jansky P., Lewis B. S., Lopez-Sendon J. L., Pais P., Parkhomenko A., Verheugt F. W. A., Zhu J., Wallentin L. Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2011;365(11):981–992. DOI:10.1056/NEJMoa1107039.; Романова М. В., Пузенко Д. В. Некоторые аспекты применения антикоагулянтов при венозных тромбоэмболиях, тромбоэмболии легочной артерии. Фокус на пожилых пациентов. Российский кардиологический журнал. 2022;27(3):97–106. DOI:10.15829/1560-4071-2022-4944.; Hylek E. M., Held C., Alexander J. H., Lopes R. D., De Caterina R., Wojdyla D. M., Huber K., Jansky P., Steg Ph. G., Hanna M., Thomas L., Wallentin L., Granger C. B. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. Journal of the American College of Cardiology. 2014;63(20):2141–2147. DOI:10.1016/j.jacc.2014.02.549.; Avezum A., Lopes R. D., Schulte P. J., Lanas F., Gersh B. J., Hanna M., Pais P., Erol C., Diaz R., Bahit M. C., Bartunek J., De Caterina R., Goto S., Ruzyllo W., Zhu J., Granger C. B., Alexander J. H. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015;132(8):624–632. DOI:10.1161/CIRCULATIONAHA.114.014807.; Lip G. Y., Keshishian A., Li X., Hamilton M., Masseria C., Gupta K., Luo X., Mardekian J., Friend K., Nadkarni A., Pan X., Baser O., Deitelzweig S. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study. Stroke. 2018;49(12):2933–2944. DOI:10.1161/STROKEAHA.118.020232.; Fralick M., Colacci M., Schneeweiss S., Huybrechts K. F., Lin K. J., Gagne J. J. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Annals of internal medicine. 2020;172(7):463–473. DOI:10.7326/M19-2522.; Rutherford O. C. W., Jonasson C., Ghanima W., Söderdahl F., Halvorsen S. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. European Heart Journal-Cardiovascular Pharmacotherapy. 2020;6(2):75–85. DOI:10.1093/ehjcvp/pvz086.; Jeong H.-C., Kim T.-E., Shin K.-H. Quantification of apixaban in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry. Translational and Clinical Pharmacology. 2019;27(1):33–41. DOI:10.12793/tcp.2019.27.1.33.; Rodina T. A., Melnikov E. S., Aksenov A. A., Belkov S. A., Sokolov A. V., Prokof’ev A. B., Ramenskaya G. V. Simultaneous Determination of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Human Blood Serum by HPLC-MS/MS for Therapeutic Drug Monitoring. Pharmaceutical Chemistry Journal. 2022;56(2):289–293. DOI:10.1007/s11094-022-02633-y.; Gouveia F., Bicker J., Santos J., Rocha M., Alves G., Falcão A., Fortuna A. Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 2020;181:113109. DOI:10.1016/j.jpba.2020.113109.; Cini M., Legnani C., Padrini R., Cosmi B., Dellanoce C., De Rosa G., Palareti G., Marcucci R., Pengo V., Poli D., Testa S. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban-and rivaroxaban-treated patients from the START-Register. International Journal of Laboratory Hematology. 2020;42(2):214–222. DOI:10.1111/ijlh.13159.; Lindahl S., Dyrkorn R., Spigset O., Hegstad S. Quantification of apixaban, dabigatran, edoxaban, and rivaroxaban in human serum by UHPLC-MS/MS – method development, validation, and application. Therapeutic drug monitoring. 2018;40(3):369. DOI:10.1097/FTD.0000000000000509.; Raghavan N., Frost C. E., Yu Z., He K., Zhang H., Humphreys W. G., Zhang D., Pinto D., Chen S., Bonacorsi S., Wong P. C. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug metabolism and disposition. 2009;37(1):74–81. DOI:10.1124/dmd.108.023143.; https://www.pharmjournal.ru/jour/article/view/1759

Dostupnost: https://www.pharmjournal.ru/jour/article/view/1759
https://doi.org/10.33380/2305-2066-2024-13-1-1684

View record from BASE

Nájsť tento článok vo Web of Science

8

Hospital consumption of direct oral anticoagulants in regions of the Russian Federation in 2017–2022 ; Потребление пероральных антикоагулянтов в стационарах регионов Российской Федерации в 2017–2022 гг.

Autoři: A. V. Matveev S. V. Glagolev K. N. Koryanova a další

Přispěvatelé: A. V. Matveev S. V. Glagolev K. N. Koryanova a další

Zdroj: Pharmacy & Pharmacology; Том 11, № 6 (2023); 461-470 ; Фармация и фармакология; Том 11, № 6 (2023); 461-470 ; 2413-2241 ; 2307-9266 ; 10.19163/2307-9266-2023-11-6

Témata: дабигатран, DOACs, consumption, rivaroxaban, apixaban, dabigatran, ПОАК, потребление, ривароксабан, апиксабан

Popis souboru: application/pdf

Relation: https://www.pharmpharm.ru/jour/article/view/1398/1017; Pharmacoepidemiology // Strom B.L., Kimmel S.E., Hennessy S., editors. 50th ed. John Wiley & Sons, Ltd. – 2012. DOI:10.1002/9781119959946; Чеберда А.Е. Исследования потребления лекарственных средств // Качественная клиническая практика. – 2017. – № 1. – С. 42–45.; Петров В.И., Герасименко А.С., Горбатенко В.С., Шаталова О.В. Фармакодинамика оральных антикоагулянтов у больных с фибрилляцией предсердий в остром периоде ишемического инсульта // Фармация и фармакология. – 2020. – Т. 8, № 4. – С. 222–232. DOI:10.19163/2307-9266-2020-8-4-222-232; Hanemaaijer S., Sodihardjo F., Horikx A., Wensing M., De Smet P.A., Bouvy M.L., Teichert M. Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands // Int J Clin Pharm. – 2015. – Vol. 37, No. 6. – P. 1128–1135. DOI:10.1007/s11096-015-0174-4; Канорский С.Г. Фибрилляция предсердий в старческом возрасте: управление рисками и особенности применения прямых пероральных антикоагулянтов // Кардиология. – 2021. – Т. 61, № 6. – С. 79–87. DOI:10.18087/cardio.2021.6.n1627; Скирденко Ю.П., Николаев Н.А. Вклад приверженности терапии антикоагулянтами в риск осложнений фибрилляции предсердий // Российский кардиологический журнал. 2019. – № 2. – С. 64–69. DOI:10.15829/1560-4071-2019-2-64-69; Консенсус экспертов по снижению риска желудочно-кишечных кровотечений у пациентов, получающих оральные антикоагулянты // Терапия. – 2021. – Т. 10, № 51. – С. 23–41. DOI:10.18565/therapy.2021.10.23-41; Вавилова Т.В., Соловьева Л.В., Бекоева А.Б., Зубкова П.Ю., Воробьева Н.А., Воробьева А.И., Мельничук Е.Ю., Хруслов М.В., Вереина Н.К., Сафин Д.Д., Галявич А.С., Sluiter M., Ендубаева Г.В., Шляхто Е.В. Лучшие практики Российской Федерации в организации антикоагулянтной терапии у больных высокого риска тромбоэмболических осложнений // Российский кардиологический журнал. – 2020. – Т. 25, № 6. – С. 3945. DOI:10.15829/1560-4071-2020-3945; Niyomsri S., Nimworapan M., Wongcharoen W., Dilokthornsakul P. Economic evaluation of direct oral anticoagulants compared to warfarin for venous thromboembolism in Thailand: a cost-utility analysis // Int J Environ Res Public Health. – 2023. – Vol. 20, No. 4. – Art. ID: 3176. DOI:10.3390/ijerph20043176; Колбин А.С., Касимова А.Р., Гиляревский С.Р. Фармакоэкономическая оценка применения апиксабана для лечения и профилактики венозных тромбоэмболий в общей популяции и популяции пациентов, страдающих онкологическими заболеваниями // Качественная клиническая практика. – 2022. – № 4. – С. 38–49. DOI:10.37489/2588-0519-2022-4-38-49; Zhao Y.J., Lin L., Zhou H.J., Tan K.T., Chew A.P., Foo C.G., Oh C.T., Lim B.P., Lim W.S. Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation // Int J Cardiol. – 2016. – Vol. 220. – P. 794–801. DOI:10.1016/j.ijcard.2016.06.087; Lorenzoni V, Pirri S, Turchetti G. Cost-effectiveness of direct non-vitamin K oral anticoagulants versus vitamin k antagonists for the management of patients with non-valvular atrial fibrillation based on available “Real-World” Evidence: The Italian National Health System Perspective // Clin Drug Investig. –2021. – Vol. 41, No. 3. – P. 255–267. DOI:10.1007/ s40261-021-01002-z; Колбин А.С., Касимова А.Р., Гиляревский С.Р. Сравнительный фармакоэкономический анализ применения апиксабана, ривароксабана и дабигатрана для профилактики развития инсульта и эмболий в сосуды большого круга кровообращения у пациентов с неклапанной фибрилляцией предсердий // Качественная клиническая практика. – 2022. – № 4. – С. 50–59. DOI:10.37489/2588-0519-2022-4-50-59; Отделенов В.А., Мирзаев К.Б., Сычёв Д.А. Возможность применения прямых пероральных антикоагулянтов для профилактики тромбоэмболических событий у пациентов с COVID-19 // Качественная клиническая практика. – 2020. – № 4S. – С. 18–22. DOI:10.37489/2588-0519-2020-S4-18-22; Отделенов В.А., Матвеев А.В., Мирзаев К.Б., Сычев Д.А. Научное обоснование и предпосылки применения прямых пероральных антикоагулянтов для профилактики тромбоэмболических осложнений у пациентов с COVID-19 // Фарматека. – 2020. – Т. 27, № 14. –С. 10–15. DOI:10.18565/pharmateca.2020.14.10-15; Yan V.K.C., Li H.L., Wei L., Knapp M.R.J., Wong I.C.K., Chan E.W. Evolving trends in consumption of direct oral anticoagulants in 65 countries/regions from 2008 to 2019 // Drugs. – 2023. – Vol. 83, No. 4. – P. 315–340. DOI:10.1007/s40265-023-01837-0; Loo S.Y., Dell’Aniello S., Huiart L., Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care // Br J Clin Pharmacol. – 2017. – Vol. 83, No. 9. –P. 2096–2106. DOI:10.1111/bcp.13299; Elewa H., Alhaddad A., Al-Rawi S., Nounou A., Mahmoud H., Singh R. Trends in oral anticoagulant use in Qatar: a 5-year experience // J Thromb Thrombolysis. – 2017. – Vol. 43, No. 3. – P. 411–416. DOI:10.1007/s11239-017-1474-4; Lippi G., Mattiuzzi C., Cervellin G., Favaloro E.J. Direct oral anticoagulants: analysis of worldwide use and popularity using google trends // Ann Transl Med. – 2017. – Vol. 5, No. 16. – Art. ID: 322. DOI:10.21037/atm.2017.06.65; Груздева А.А., Хохлов А.Л., Ильин М.В. Оральные антикоагулянты в профилактике тромоэмболических осложнений у кардиологических пациентов: анализ применения в Российской Федерации // Качественная клиническая практика. – 2020. – № 1. – С. 69–79. DOI:10.37489/2588-0519-2020-1-69-79; Воробьева Н.А., Воробьева А.И., Шемякина Н.Я., Алексеева А.С. Пациент-ориентированный подход как основа повышения эффективности и безопасности антитромботической терапии коморбидных пациентов. Роль антикоагулянтных кабинетов // Клиническая геронтология. – 2019. – Т. 25, № 11–12. – С. 19–24. DOI:10.26347/1607-2499201911-12019-024; Улумбекова Г.Э., Калашникова А.В. Подходы к формированию концепции национальной лекарственной политики. Часть 1. Анализ рынка лекарственных препаратов в РФ. ОРГЗДРАВ: новости, мнения, обучение // Вестник ВШОУЗ. – 2018. – Т. 4. – С. 53–75. DOI:10.24411/2411-8621-2018-14003; Сычев Д.А., Абдуллаев Ш.П., Мирзаев К.Б., Рыжикова К.А., Шуев Г.Н., Гришина Е.А., Созаева Ж.А., Маммаев С.Н., Гафуров Д.М., Китаева Е.Ю., Шпрах В.В., Сулейманов С.Ш., Болиева Л.З., Созаева М.С., Жучкова С.М., Гималдинова Н.Е., Сидукова Е.Е., Асоскова А.В., Мумладзе Р.Б. Генетические детерминанты безопасности применения прямого ингибитора тромбина среди этнических групп Российской Федерации // Биомедицина. – 2019. – № 1. – С. 78–94. DOI:10.33647/2074-5982-15-1-78-94; Скрипка А.И., Когай В.В., Листратов А.И., Соколова А.А., Напалков Д.А., Фомин В.В. Персонализированный подход к назначению прямых оральных антикоагулянтов: от теории к практике // Терапевтический архив. – 2019. – Т. 91, № 7. – С. 111–120. DOI:10.26442/00403660.2019.07.000045; Мирзаев К.Б., Иващенко Д.В., Володин И.В., Гришина Е.А., Акмалова К.А., Качанова А.А., Скрипка А.И., Миннигулов Р.М., Морозова Т.Е., Батурина О.А., Леванов А.Н., Шелехова Т.В., Калинкин А.И., Напалков Д.А., Соколова А.А., Андреев Д.А., Сычев И.Н., Бочков П.О., Сычев Д.А. Новые фармакогенетические маркеры риска кровотечений на фоне применения прямых оральных антикоагулянтов // Рациональная фармакотерапия в кардиологии. – 2020. – Т. 16, № 5. – С. 670–677. DOI:10.20996/1819-6446-2020-10-05; https://www.pharmpharm.ru/jour/article/view/1398

Dostupnost: https://www.pharmpharm.ru/jour/article/view/1398
https://doi.org/10.19163/2307-9266-2023-11-6-461-470

View record from BASE

Nájsť tento článok vo Web of Science

9

Ten rules for oral anticoagulants prescription after a stroke ; 10 правил назначения пероральных антикоагулянтов после инсульта

Autoři: A. A. Kulesh D. A. Demin S. S. Kucherenko a další

Přispěvatelé: A. A. Kulesh D. A. Demin S. S. Kucherenko a další

Zdroj: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 4 (2024); 111-121 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 4 (2024); 111-121 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-4

Témata: апиксабан, oral anticoagulants, apixaban, пероральные антикоагулянты

Popis souboru: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2341/1709; https://nnp.ima-press.net/nnp/article/view/2341/1712; Seiffge DJ, Werring DJ, Paciaroni M, et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019 Jan;18(1):117-26. doi:10.1016/S1474-4422(18)30356-9. Epub 2018 Nov 8.; Кулеш АА, Демин ДА. Вопросы совершенствования ведения пациентов, перенесших ишемический инсульт на фоне фибрилляции предсердий. Неврология, нейропсихиатрия, психосоматика. 2022;14(6):115-21. doi:10.14412/2074-2711-2022-6-115-121; Diener HC, Hankey GJ. Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar. J Am Coll Cardiol. 2020 Apr 21;75(15):1804-18. doi:10.1016/j.jacc.2019.12.072; Hart RG, Coull BM, Hart D. Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke. 1983 Sep-Oct;14(5):688-93. doi:10.1161/01.str.14.5.688; Muscari A, Faccioli L, Lega MV, et al. Predicting hemorrhagic transformation and its timing from maximum cerebral lesion diameter in nonlacunar ischemic strokes. Brain Behav. 2020 Jan;10(1):e01497. doi:10.1002/brb3.1497. Epub 2019 Dec 17.; Кулеш АА. Чистая клиническая выгода (net clinical benefit) антикоагулянтной терапии с точки зрения невролога. Consilium Medicum. 2022;24(2):79-84. doi:10.26442/20751753.2022.2.201537; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62. doi:10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.; Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi:10.1056/NEJMoa1107039. Epub 2011 Aug 27.; Proietti M, Romanazzi I, Romiti GF, et al. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation : A Systematic Review and Meta-Analysis. Stroke. 2018 Jan;49(1):98-106. doi:10.1161/STROKEAHA.117.018395. Epub 2017 Nov 22.; Ray WA, Chung CP, Stein CM, et al. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. JAMA. 2021 Dec 21;326(23):2395-404. doi:10.1001/jama.2021.21222; Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3;364(9):806-17. doi:10.1056/NEJMoa1007432. Epub 2011 Feb 10.; Kamel H, Longstreth WT Jr, Tirschwell DL, et al; ARCADIA Investigators. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial. JAMA. 2024 Feb 20;331(7):573-81. doi:10.1001/jama.2023.27188; Buckley BJR, Lane DA, Calvert P, et al. Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation : A Systematic Review and Meta-Analysis. J Clin Med. 2022 Jun 30;11(13):3788. doi:10.3390/jcm11133788; Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi:10.1161/STR.0000000000000375. Epub 2021 May 24.; Joglar JA, Chung MK, Armbruster AL, et al; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jan 2;149(1):e1-e156. doi:10.1161/CIR.0000000000001193. Epub 2023 Nov 30.; Noubiap JJ, Nyaga UF, Ndoadoumgue AL, et al. Meta-Analysis of the Incidence, Prevalence, and Correlates of Atrial Fibrillation in Rheumatic Heart Disease. Glob Heart. 2020 May 18;15(1):38. doi:10.5334/gh.807; Vahanian A, Beyersdorf F, Praz F, et al; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632. doi:10.1093/eurheartj/ehab395. Erratum in: Eur Heart J. 2022 Jun 1;43(21):2022. doi:10.1093/eurheartj/ehac051; Connolly SJ, Karthikeyan G, Ntsekhe M, et al; INVICTUS Investigators. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. N Engl J Med. 2022 Sep 15;387(11):978-88. doi:10.1056/NEJMoa2209051. Epub 2022 Aug 28.; Steffel J, Collins R, Antz M, et al; External reviewers. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Oct 9;23(10):1612-76. doi:10.1093/europace/euab065. Erratum in: Europace. 2021 Oct 9;23(10):1676. doi:10.1093/europace/euab157; Eikelboom JW, Connolly SJ, Brueckmann M, et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206-14. doi:10.1056/NEJMoa1300615. Epub 2013 Aug 31.; Wang TY, Svensson LG, Wen J, et al. Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve. NEJM Evid. 2023 Jul;2(7):EVIDoa2300067. doi:10.1056/EVIDoa2300067. Epub 2023 May 6.; Alrohimi A, Jickling G, Buck B, Butcher KS. Timing of Anticoagulation after Acute Ischemic Stroke in Patients with Atrial Fibrillation. Can J Neurol Sci. 2023 Jul;50(4):503-14. doi:10.1017/cjn.2022.268; Kimura S, Toyoda K, Yoshimura S, et al; SAMURAI, RELAXED, RAF, RAF-NOAC, CROMIS-2, NOACISP LONGTERM, Erlangen Registry and Verona Registry Investigators. Practical “1-2-3-4-Day” Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. Stroke. 2022 Feb 2:STROKEAHA121036695. doi:10.1161/STROKEAHA.121.036695. Epub 2022 Feb 2; Oldgren J, Asberg S, Hijazi Z, et al; National TIMING Collaborators. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. Circulation. 2022 Oct 4;146(14):1056-66. doi:10.1161/CIRCULATIONAHA.122.060666. Epub 2022 Sep 6.; Fischer U, Koga M, Strbian D, et al; ELAN Investigators. Early versus Later Anticoagulation for Stroke with Atrial Fibrillation. N Engl J Med. 2023 Jun 29;388(26):2411-21. doi:10.1056/NEJMoa2303048. Epub 2023 May 24.; Tirumandyam G, Krishna Mohan GV, Addi Palle LR, et al. Early Versus Delayed Oral Anticoagulation in Patients With Acute Ischemic Stroke Due to Atrial Fibrillation: A Meta-Analysis. Cureus. 2023 Jun 22;15(6):e40801. doi:10.7759/cureus.40801; Alrohimi A, Rose DZ, Burgin WS, et al. Risk of hemorrhagic transformation with early use of direct oral anticoagulants after acute ischemic stroke: A pooled analysis of prospective studies and randomized trials. Int J Stroke. 2023 Aug;18(7):864-72. doi:10.1177/17474930231164891. Epub 2023 Mar 26.; Goeldlin MB, Hakim A, Branca M, et al; ELAN Investigators. Early vs Late Anticoagulation in Minor, Moderate, and Major Ischemic Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial. JAMA Neurol. 2024 May 28:e241450. doi:10.1001/jamaneurol.2024.1450; Yasaka M, Koretsune Y, Yamashita T, et al. Recurrent Stroke and Bleeding Events after Acute Cardioembolic Stroke-Analysis Using Japanese Healthcare Database from Acute-Care Institutions. J Stroke Cerebrovasc Dis. 2018 Apr;27(4):1012-24. doi:10.1016/j.jstrokecerebrovasdis.2017.11.002. Epub 2017 Dec 12.; Кулеш АА, Янишевский СН, Демин ДА и др. Пациент с некардиоэмболическим ишемическим инсультом или транзиторной ишемической атакой высокого риска. Часть 1. Диагностика. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):10-8. doi:10.14412/2074-2711-2023-2-10-18; Кулеш АА, Янишевский СН, Демин ДА и др. Пациент с некардиоэмболическим ишемическим инсультом или транзиторной ишемической атакой высокого риска. Часть 2. Вторичная профилактика. Неврология, нейропсихиатрия, психосоматика. 2023;15(3):4-10. doi:10.14412/2074-2711-2023-3-4-10; Yaghi S, Willey JZ, Cucchiara B, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research. Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017 Dec;48(12):e343-e361. doi:10.1161/STR.0000000000000152. Epub 2017 Nov 2.; Tong X, Burgin WS, Ren Z, et al; ANGEL-ACT Study Group. Association of Stroke Subtype With Hemorrhagic Transformation Mediated by Thrombectomy Pass: Data From the ANGEL-ACT Registry. Stroke. 2022 Jun;53(6):1984-92. doi:10.1161/STROKEAHA.121.037411. Epub 2022 Mar 31.; Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008 Aug;39(8):2249-56. doi:10.1161/STROKEAHA.107.510321. Epub 2008 Jun 5.; Vaclavik D, Vilionskis A, Jatuzis D, et al. Clinical outcome of cardioembolic stroke treated by intravenous thrombolysis. Acta Neurol Scand. 2018 Mar;137(3):347-55. doi:10.1111/ane.12880. Epub 2017 Dec 8.; Tian B, Tian X, Shi Z, et al; DIRECT-MT Investigators. Clinical and Imaging Indicators of Hemorrhagic Transformation in Acute Ischemic Stroke After Endovascular Thrombectomy. Stroke. 2022 May;53(5):1674-81. doi:10.1161/STROKEAHA.121.035425.; Sandset EC, Anderson CS, Bath PM, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J. 2021 Jun;6(2):XLVIII-LXXXIX. doi:10.1177/23969873211012133. Epub 2021 May 11.; Wang X, Minhas JS, Moullaali TJ, et al; ENCHANTED Investigators. Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study. Stroke. 2022 Mar;53(3):779-87. doi:10.1161/STROKEAHA.121.034580. Epub 2021 Oct 27.; Morris NA, Jindal G, Chaturvedi S. Intensive Blood Pressure Control After Mechanical Thrombectomy for Acute Ischemic Stroke. Stroke. 2023 May;54(5):1457-61. doi:10.1161/STROKEAHA.122.041949. Epub 2023 Apr 6.; Nishimoto T, Oka F, Okazaki K, Ishihara H. Timing of Direct Oral Anticoagulants for Hemorrhagic Transformation After Endovascular Treatment in Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2022 Jul;31(7):106507. doi:10.1016/j.jstrokecerebrovasdis.2022.106507. Epub 2022 Apr 28.; Li L, Poon MTC, Samarasekera NE, et al. Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies. Lancet Neurol. 2021 Jun;20(6):437-47. doi:10.1016/S1474-4422(21)00075-2; Kuramatsu JB, Huttner HB. Management of oral anticoagulation after intracerebral hemorrhage. Int J Stroke. 2019 Apr;14(3):238-46. doi:10.1177/1747493019828555. Epub 2019 Feb 14.; Moon JY, Bae GH, Jung J, Shin DH. Restarting anticoagulant therapy after intracranial hemorrhage in patients with atrial fibrillation: A nationwide retrospective cohort study. Int J Cardiol Heart Vasc. 2022 Apr 26;40:101037. doi:10.1016/j.ijcha.2022.101037; Lin SY, Chang YC, Lin FJ, et al. Post-Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation. J Am Heart Assoc. 2022 Mar 15;11(6):e022849. doi:10.1161/JAHA.121.022849. Epub 2022 Mar 4.; Greenberg SM, Ziai WC, Cordonnier C, et al; American Heart Association/American Stroke Association. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022 Jul;53(7):e282-e361. doi:10.1161/STR.0000000000000407. Epub 2022 May 17.; Zhou Q, Liu X, Yang X, et al. Efficacy and safety of anticoagulation in atrial fibrillation patients with intracranial hemorrhage : A systematic review and meta-analysis. Front Pharmacol. 2023 Mar 9;14:1122564. doi:10.3389/fphar.2023.1122564; Wang X, Wen D, Chen Y, et al. Anticoagulation medication in nontraumatic intracranial hemorrhage survivors with atrial fibrillation. J Thromb Thrombolysis. 2023 Jul;56(1):1-11. doi:10.1007/s11239-023-02804-y. Epub 2023 Apr 6.; Кулеш АА. Современные подходы к диагностике при внутримозговом кровоизлиянии. Неврология, нейропсихиатрия, психосоматика. 2020;12(2):4-11. doi:10.14412/2074-2711-2020-2-4-11; Кулеш АА, Сыромятникова ЛИ. Терапия оральными антикоагулянтами у пациентов после внутримозгового кровоизлияния. Неврология, нейропсихиатрия, психосоматика. 2020;12(3):4-10. doi:10.14412/2074-2711-2020-3-4-10; Кулеш АА, Дробаха ВЕ, Шестаков ВВ. Церебральная спорадическая неамилоидная микроангиопатия: патогенез, диагностика и особенности лечебной тактики. Неврология, нейропсихиатрия, психосоматика. 2018;10(4):13-22. doi:10.14412/2074-2711-2018-4-13-22; Кулеш АА, Дробаха ВЕ, Шестаков ВВ. Церебральная болезнь мелких сосудов: классификация, клинические проявления, диагностика и особенности лечения. Неврология, нейропсихиатрия, психосоматика. 2019;11(3S):4-17. doi:10.14412/2074-2711-2019-3S-4-17; Новосадова ОА, Кулеш АА, Григорьева ВН. Диагностика церебральной амилоидной ангиопатии: на пути к Бостонским критериям 2.0. Российский неврологический журнал. 2020;25(5):4-13. doi:10.30629/2658-7947-2020-25-5-4-13; Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for research into small vessel disease-advances since 2013. Lancet Neurol. 2023 Jul;22(7):602-18. doi:10.1016/S1474-4422(23)00131-X. Epub 2023 May 23.; Zanon Zotin MC, Makkinejad N, Schneider JA, et al. Sensitivity and Specificity of the Boston Criteria Version 2.0 for the Diagnosis of Cerebral Amyloid Angiopathy in a Community-Based Sample. Neurology. 2024 Jan 9;102(1):e207940. doi:10.1212/WNL.0000000000207940. Epub 2023 Dec 13.; Charidimou A, Boulouis G, Roongpiboonsopit D, et al. Cortical superficial siderosis and recurrent intracerebral hemorrhage risk in cerebral amyloid angiopathy: Large prospective cohort and preliminary meta-analysis. Int J Stroke. 2019 Oct;14(7):723-33. doi:10.1177/1747493019830065. Epub 2019 Feb 20.; Wu J, Liu Z, Yao M, et al. Clinical characteristics of cerebral amyloid angiopathy and risk factors of cerebral amyloid angiopathy related intracerebral hemorrhage. J Neurol. 2024 May 26. doi:10.1007/s00415-024-12451-9. Online ahead of print.; Soo Y, Zietz A, Yiu B, et al; Microbleeds International Collaborative Network. Impact of Cerebral Microbleeds in Stroke Patients with Atrial Fibrillation. Ann Neurol. 2023 Jul;94(1):61-74. doi:10.1002/ana.26642. Epub 2023 Apr 17.; Marti-Fabregas J, Camps-Renom P, Best JG, et al; Microbleeds International Collaborative Network (MICON). Stroke Risk and Antithrombotic Treatment During Follow-up of Patients With Ischemic Stroke and Cortical Superficial Siderosis. Neurology. 2023 Mar 21;100(12):e1267-e1281. doi:10.1212/WNL.0000000000201723. Epub 2022 Dec 19.; Kozberg MG, Perosa V, Gurol ME, van Veluw SJ. A practical approach to the management of cerebral amyloid angiopathy. Int J Stroke. 2021 Jun;16(4):356-69. doi:10.1177/1747493020974464. Epub 2020 Nov 29.; Merella P, Casu G, Chessa P, et al. When Atrial Fibrillation Meets Cerebral Amyloid Angiopathy: Current Evidence and Strategies. J Clin Med. 2023 Dec 15;12(24):7704. doi:10.3390/jcm12247704; Pennlert J, Overholser R, Asplund K, et al. Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation. Stroke. 2017 Feb;48(2):314-20. doi:10.1161/STROKEAHA.116.014643. Epub 2016 Dec 20.; Nielsen PB, Larsen TB, Skjoth F, et al. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. Circulation. 2015 Aug 11;132(6):517-25. doi:10.1161/CIRCULATIONAHA.115.015735. Epub 2015 Jun 9.; Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015 Feb 24;313(8):824-36. doi:10.1001/jama.2015.0846; Park YA, Uhm JS, Pak HN, et al. Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. Heart Rhythm. 2016 Sep;13(9):1794-802. doi:10.1016/j.hrthm.2016.05.016; Kojima G. Frailty Defined by FRAIL Scale as a Predictor of Mortality : A Systematic Review and Meta-analysis. J Am Med Dir Assoc. 2018 Jun;19(6):480-3. doi:10.1016/j.jamda.2018.04.006; Desai R, Li A, Mondal A, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonist (Warfarin) For Stroke Prevention In Frail Patients With Atrial Fibrillation: A Meta-Analysis. Proc (Bayl Univ Med Cent). 2022 Dec 22;36(2):274-5. doi:10.1080/08998280.2022.2155926; Grymonprez M, Petrovic M, De Backer TL, et al. Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J Qual Care Clin Outcomes. 2024 Jan 12;10(1):55-65. doi:10.1093/ehjqcco/qcad019; Galvain T, Hill R, Donegan S, et al. Efficacy and Safety of Anticoagulants in Patients with Atrial Fibrillation and History of Falls or Risk of Falls : A Systematic Review and Multilevel Meta-Analysis. Drug Saf. 2022 Nov;45(11):1349-62. doi:10.1007/s40264-022-01231-x. Epub 2022 Sep 19.; Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018 Dec;49(12):2933-44. doi:10.1161/STROKEAHA.118.020232; Bonanad C, Formiga F, Anguita M, et al. Oral Anticoagulant Use and Appropriateness in Elderly Patients with Atrial Fibrillation in Complex Clinical Conditions: ACONVENIENCE Study. J Clin Med. 2022 Dec 14;11(24):7423. doi:10.3390/jcm11247423; Парфенов ВА, Кулеш АА. Цереброваскулярное заболевание с когнитивными нарушениями. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(9):121-30. doi:10.17116/jnevro2021121091121; Кулеш АА, Емелин АЮ, Боголепова АН и др. Клинические проявления и вопросы диагностики хронического цереброваскулярного заболевания (хронической ишемии головного мозга) на ранней (додементной) стадии. Неврология, нейропсихиатрия, психосоматика. 2021;13(1):4-12. doi:10.14412/2074-2711-2021-1-4-12; Madhavan M, Graff-Radford J, Piccini JP, Gersh BJ. Cognitive dysfunction in atrial fibrillation. Nat Rev Cardiol. 2018 Dec;15(12):744-56. doi:10.1038/s41569-018-0075-z; Lin KJ, Singer DE, Bykov K, et al. Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation. JAMA Netw Open. 2023 Mar 1;6(3):e234086. doi:10.1001/jamanetworkopen.2023.4086; Grymonprez M, Petrovic M, De Backer TL, et al. Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study. Age Ageing. 2023 Mar 1;52(3):afad038. doi:10.1093/ageing/afad038; Luca F, Oliva F, Abrignani MG, et al. Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios. J Clin Med. 2023 Sep 13;12(18):5955. doi:10.3390/jcm12185955; Paciaroni M, Agnelli G, Caso V, et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke. 2019 Aug;50(8):2168-74. doi:10.1161/STROKEAHA.119.025350. Epub 2019 Jun 25.; Katsi V, Georgiopoulos G, Skafida A, et al. Noncardioembolic Stroke in Patients with Atrial Fibrillation. Angiology. 2019 Apr;70(4):299-304. doi:10.1177/0003319718791711. Epub 2018 Jul 31.; Ip YMB, Lau KK, Ko H, et al. Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant. Neurology. 2023 Jul 25;101(4):e358-e369. doi:10.1212/WNL.0000000000207422. Epub 2023 May 24.; Deitelzweig S, Kang A, Jiang J, et al. Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation. J Clin Med. 2024 Feb 14;13(4):1073. doi:10.3390/jcm13041073; Healey JS, Eikelboom J, Douketis J, et al; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012 Jul 17;126(3):343-8. doi:10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14.; Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med. 2019 Nov 1;179(11):1469-78. doi:10.1001/jamainternmed.2019.2431; Liu X, Huang M, Ye C, et al. Effect of non-recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: A meta-analysis. Clin Cardiol. 2021 Apr;44(4):472-80. doi:10.1002/clc.23586. Epub 2021 Mar 7.; Ashraf H, Agasthi P, Shanbhag A, et al. Long-Term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Atrial Flutter. Am J Med. 2021 Jun;134(6):788-96. doi:10.1016/j.amjmed.2020.12.022. Epub 2021 Jan 12.

Dostupnost: https://nnp.ima-press.net/nnp/article/view/2341
https://doi.org/10.14412/2074-2711-2024-4-111-121

View record from BASE

Nájsť tento článok vo Web of Science

10

Atrial fibrillation and multimorbidity: How to choose the perfect direct oral anticoagulant? ; Фибрилляция предсердий и полиморбидность: как выбрать идеальный прямой оральный антикоагулянт?

Autoři: O. D. Ostroumova A. V. Dubinina S. S. Telkova a další

Zdroj: Meditsinskiy sovet = Medical Council; № 16 (2024); 54-62 ; Медицинский Совет; № 16 (2024); 54-62 ; 2658-5790 ; 2079-701X

Témata: апиксабан, coronary artery disease, chronic kidney disease, anemia, multimorbidity, direct oral anticoagulants, apixaban, хроническая болезнь почек, анемия, прямые оральные антикоагулянты

Popis souboru: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8612/7560; Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–221. https://doi.org/10.1177/1747493019897870.; Kavousi M. Differences in Epidemiology and Risk Factors for Atrial Fibrillation Between Women and Men. Front Cardiovasc Med. 2020;7:3. https://doi.org/10.3389/fcvm.2020.00003.; Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020;127(1):4–20. https://doi.org/10.1161/CIRCRESAHA.120.316340.; Ohlrogge AH, Brederecke J, Schnabel RB. Global Burden of Atrial Fibrillation and Flutter by National Income: Results From the Global Burden of Disease 2019 Database. J Am Heart Assoc. 2023;12(17):e030438. https://doi.org/10.1161/JAHA.123.030438.; Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042–1046. https://doi.org/10.1161/01.CIR.0000140263.20897.42.; Ардашев АВ, Беленков ЮН, Матюкевич МЧ, Снежицкий ВА. Фибрилляция предсердий и смертность: прогностические факторы и терапевтические стратегии. Кардиология. 2021;61(2):91–98. https://doi.org/10.18087/cardio.2021.2.n1348.; Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–952. https://doi.org/10.1161/01.cir.98.10.946.; Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–847. https://doi.org/10.1161/CIRCULATIONAHA.113.005119.; Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125. https://doi.org/10.1161/CIRCULATIONAHA.105.595140.; Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546–554. https://doi.org/10.1212/01.wnl.0000267275.68538.8d.; Forman DE, Goyette RE. Oral anticoagulation therapy for elderly patients with atrial fibrillation: utility of bleeding risk covariates to better understand and moderate risks. Clin Appl Thromb Hemost. 2014;20(1):5–15. https://doi.org/10.1177/1076029613492010.; Van den Bussche H, Koller D, Kolonko T, Hansen H, Wegscheider K, Glaeske G et al. Which chronic diseases and disease combinations are specific to multimorbidity in the elderly? Results of a claims data based crosssectional study in Germany. BMC Public Health. 2011;11:101. https://doi.org/10.1186/1471-2458-11-101.; LaMori JC, Mody SH, Gross HJ, daCosta DiBonaventura M, Patel AA, Schein JR, Nelson WW. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53–62. https://doi.org/10.1177/1753944712464101.; Kozieł M, Teutsch C, Halperin JL, Rothman KJ, Diener HC, Ma CS et al. Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. PLoS ONE. 2021;16(4):e0249524. https://doi.org/10.1371/journal.pone.0249524.; Vanbeselaere V, Truyers C, Elli S, Buntinx F, De Witte H, Degryse J et al. Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study. BMC Cardiovasc Disord. 2016;16:61. https://doi.org/10.1186/s12872-016-0235-1.; Van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009;40(4):1410–1416. https://doi.org/10.1161/STROKEAHA.108.526988.; Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393. https://doi.org/10.1093/eurheartj/ehy136.; Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010;31(8):967–975. https://doi.org/10.1093/eurheartj/ehn599.; Fumagalli S, Said SA, Laroche C, Gabbai D, Boni S, Marchionni N et al. Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. Eur Heart J Cardiovasc Pharmacother. 2018;4(3):172–179. https://doi.org/10.1093/ehjcvp/pvx037.; Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;159(6):1102–1107. https://doi.org/10.1016/j.ahj.2010.03.027.; Ananthapanyasut W, Napan S, Rudolph EH, Harindhanavudhi T, Ayash H, Guglielmi KE, Lerma EV. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(2):173–181. https://doi.org/10.2215/CJN.03170509.; Wetmore JB, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Spertus JA et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int. 2012;81(5):469–476. https://doi.org/10.1038/ki.2011.416.; Дружилов МА, Кузнецова ТЮ, Дружилова ОЮ, Арустамова УД, Гаврилов ДВ, Гусев АВ. Фибрилляция предсердий и хроническая болезнь почек: основные клинические характеристики пациентов в отдельных субъектах Российской Федерации. Кардиоваскулярная терапия и профилактика. 2023;22(4):3544. https://doi.org/10.15829/1728-8800-2023-3544.; Yao RJR, Holmes DN, Andrade JG, Levin A, Piccini JP, Fordyce CB. Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT-AF II. J Am Heart Assoc. 2023;12(6):e026605. https://doi.org/10.1161/JAHA.122.026605.; Cha MJ, Cho Y, Oh IY, Choi EK, Oh S. Validation of Conventional Thromboembolic Risk Factors in a Korean Atrial Fibrillation Population – Suggestion for a Novel Scoring System, CHA2DS2-VAK. Circ J. 2018;82(12):2970–2975. https://doi.org/10.1253/circj.CJ-18-0218.; Liao JN, Chao TF, Liu CJ, Wang KL, Chen SJ, Lin YJ et al. Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int. 2015;87(6):1209–1215. https://doi.org/10.1038/ki.2014.393.; Nelson SE, Shroff GR, Li S, Herzog CA. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. J Am Heart Assoc. 2012;1(4):e002097. https://doi.org/10.1161/JAHA.112.002097.; Arnson Y, Hoshen M, Berliner-Sendrey A, Reges O, Balicer R, Leibowitz M et al. Risk of Stroke, Bleeding, and Death in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease. Cardiology. 2020;145(3):178–186. https://doi.org/10.1159/000504877.; Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L et al. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD – AF Registry. J Am Heart Assoc. 2019;8(3):e010510. https://doi.org/10.1161/JAHA.118.010510.; Аракелян МГ, Бокерия ЛА, Васильева ЕЮ, Голицын СП, Голухова ЕЗ, Горев МВ и др. Фибрилляция и трепетание предсердий у взрослых: клинические рекомендации. М.; 2020. 152 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/382_1.; Bonde AN, Lip GY, Kamper AL, Fosbøl EL, Staerk L, Carlson N et al. Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study. Stroke. 2016;47(11):2707–2713. https://doi.org/10.1161/STROKEAHA.116.014422.; Sitticharoenchai P, Takkavatakarn K, Boonyaratavej S, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P. Non-Vitamin K Antagonist Oral Anticoagulants Provide Less Adverse Renal Outcomes Than Warfarin In Non-Valvular Atrial Fibrillation: A Systematic Review and MetaAnalysis. J Am Heart Assoc. 2021;10(7):e019609. https://doi.org/10.1161/JAHA.120.019609.; Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129(9):961–970. https://doi.org/10.1161/CIRCULATIONAHA.113.003628.; Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821–2830. https://doi.org/10.1093/eurheartj/ehs274.; Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G et al. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. Circulation. 2017;135(10):1001–1003. https://doi.org/10.1161/CIRCULATIONAHA.116.024666.; Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016;134(1):24–36. https://doi.org/10.1161/CIRCULATIONAHA.116.022361.; Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331–339. https://doi.org/10.1016/j.ahj.2009.07.035.; Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016;1(4):451–460. https://doi.org/10.1001/jamacardio.2016.1170.; Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation. 2020;141(17):1384–1392. https://doi.org/10.1161/CIRCULATIONAHA.119.044059.; Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease – Double trouble. Adv Med Sci. 2018;63(1):30–35. https://doi.org/10.1016/j.advms.2017.06.005.; Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174(1):107–114. https://doi.org/10.1001/jamainternmed.2013.11912.; Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30(9):1038–1045. https://doi.org/10.1093/eurheartj/ehn579.; Wang TY, Robinson LA, Ou FS, Roe MT, Ohman EM, Gibler WB et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J. 2008;155(2):361–368. https://doi.org/10.1016/j.ahj.2007.09.003.; Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010;103(1):13–28. https://doi.org/10.1160/TH09-08-0580.; Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA, Roger VL. Atrial fibrillation and death after myocardial infarction: a community study. Circulation. 2011;123(19):2094–2100. https://doi.org/10.1161/CIRCULATIONAHA.110.990192.; Alasady M, Abhayaratna WP, Leong DP, Lim HS, Abed HS, Brooks AG et al. Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction. Heart Rhythm. 2011;8(7):955–960. https://doi.org/10.1016/j.hrthm.2011.02.016.; Batra G, Svennblad B, Held C, Jernberg T, Johanson P, Wallentin L, Oldgren J. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart. 2016;102(12):926–933. https://doi.org/10.1136/heartjnl-2015-308678.; Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. https://doi.org/10.1093/eurheartj/ehx393.; Bahit MC, Lopes RD, Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol. 2013;170(2):215–220. https://doi.org/10.1016/j.ijcard.2013.10.062.; Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339(23):1665–1671. https://doi.org/10.1056/NEJM199812033392303.; Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–1912. https://doi.org/10.1016/S0140-6736(06)68845-4.; Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967–1974. https://doi.org/10.1016/S0140-6736(09)61751-7.; Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–1441. https://doi.org/10.1001/archinternmed.2010.271.; Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380(16):1509–1524. https://doi.org/10.1056/NEJMoa1817083.; Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375(25):2423–2434. https://doi.org/10.1056/NEJMoa1611594.; Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561.; Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377(16):1513–1524. https://doi.org/10.1056/NEJMoa1708454.; Westenbrink BD, Alings M, Connolly SJ, Eikelboom J, Ezekowitz MD, Oldgren J et al. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial. J Thromb Haemost. 2015;13(5):699–707. https://doi.org/10.1111/jth.12874.; Westenbrink BD, Alings M, Granger CB, Alexander JH, Lopes RD, Hylek EM et al. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2017;185:140–149. https://doi.org/10.1016/j.ahj.2016.12.008.; Tu SJ, Hanna-Rivero N, Elliott AD, Clarke N, Huang S, Pitman BM et al. Associations of anemia with stroke, bleeding, and mortality in atrial fibrillation: A systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2021;32(3):686–694. https://doi.org/10.1111/jce.14898.; Bonde AN, Blanche P, Staerk L, Gerds TA, Gundlund A, Gislason G et al. Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study. Eur Heart J. 2019;40(46):3782–3790. https://doi.org/10.1093/eurheartj/ehz155.; Puurunen M, Kiviniemi T, Nammas W, Schlitt A, Rubboli A, Nyman K et al. Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. BMJ Open. 2014;4(5):e004700. https://doi.org/10.1136/bmjopen-2013-004700.; Alboni P, Stucci N, Messop AC. Il trattamento anticoagulante nei pazienti con fibrillazione atriale non valvolare e anemia cronica: ancora zone grigie. G Ital Cardiol (Rome). 2021;22(4):311–318. https://doi.org/10.1714/3574.35577.; Tanaka N, Inoue K, Okada M, Sakata Y, Akao M, Yamashita T et al. Impact of anemia on the clinical outcomes in elderly patients with atrial fibrillation receiving apixaban: J-ELD AF registry subanalysis. Int J Cardiol Heart Vasc. 2022;40:100994. https://doi.org/10.1016/j.ijcha.2022.100994.; Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N et al. Association of Cardiometabolic Multimorbidity With Mortality. JAMA. 2015;314(1):52–60. https://doi.org/10.1001/jama.2015.7008.; Fan J, Sun Z, Yu C, Guo Y, Pei P, Yang L et al. Multimorbidity patterns and association with mortality in 0.5 million Chinese adults. Chin Med J (Engl). 2022;135(6):648–657. https://doi.org/10.1097/CM9.0000000000001985.; Kato D, Kawachi I, Saito J, Kondo N. Complex multimorbidity and mortality in Japan: a prospective propensity-matched cohort study. BMJ Open. 2021;11(8):e046749. https://doi.org/10.1136/bmjopen-2020-046749.

Dostupnost: https://www.med-sovet.pro/jour/article/view/8612
https://doi.org/10.21518/ms2024-388

View record from BASE

Nájsť tento článok vo Web of Science

11

POSSIBILITIES FOR RAPID MONITORING OF THE ANTITHROMBOTIC EFFECTIVENESS OF APIXABAN

Autoři: Solovev М. Gulyaev N. Kotlovskaya L. a další

Témata: низкочастотная пьезотромбоэластография, гемостатический потенциал, противотромботическая терапия, персонификация, апиксабан, НОАК, low-frequency piezothromboelastography, hemostatic potential, antithrombotic therapy, personification, apixaban, NOAC

Nájsť tento článok vo Web of Science

12

Oral anticoagulants in the prevention of thromboembolic complications in cardiac patients: analysis of use in the Russian Federation

Autoři: A. A. Gruzdeva A. A. Khokhlov M. V. Ilyin

Zdroj: Качественная клиническая практика, Vol 0, Iss 1, Pp 69-79 (2020)

Témata: 2. Zero hunger, варфарин, апиксабан, дабигатран, 3. Good health, RS1-441, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, ривароксабан, Medical technology, персонализированный выбор антикоагулянта, R855-855.5, фармакогенетический подход

Přístupová URL adresa: https://www.clinvest.ru/jour/article/download/491/494
https://doaj.org/article/44c980bd16aa4ab28ad5de4a09f5d47d
https://cyberleninka.ru/article/n/oralnye-antikoagulyanty-v-profilaktike-tromoembolicheskih-oslozhneniy-u-kardiologicheskih-patsientov-analiz-primeneniya-v-rossiyskoy
https://www.clinvest.ru/jour/article/view/491
https://cyberleninka.ru/article/n/oralnye-antikoagulyanty-v-profilaktike-tromoembolicheskih-oslozhneniy-u-kardiologicheskih-patsientov-analiz-primeneniya-v-rossiyskoy/pdf
https://www.clinvest.ru/jour/article/download/491/494

View record at OpenAIRE

Nájsť tento článok vo Web of Science

13

Laboratory Predictors of Hemorrhagic Complications in Patients With Total Hip Arthroplasty and Treatment With Direct Oral Anticoagulants ; Лабораторные предикторы геморрагических осложнений при эндопротезировании тазобедренных суставов на фоне приема пероральных антикоагулянтов

Autoři: L. B. Gaikovaya K. N. Zamyatina A. N. Tkachenko a další

Zdroj: Russian Sklifosovsky Journal "Emergency Medical Care"; Том 12, № 3 (2023); 369-375 ; Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»; Том 12, № 3 (2023); 369-375 ; 2541-8017 ; 2223-9022

Témata: кровотечение, apixaban, total hip arthroplasty, hemostasis, bleeding, апиксабан, эндопротезирование тазобедренного сустава, гемостаз

Popis souboru: application/pdf

Relation: https://www.jnmp.ru/jour/article/view/1669/1333; https://www.jnmp.ru/jour/article/view/1669/1394; Жирова Т.А., Лыков М.С., Зырянов М.Н., Бабушкин В.Н. Новые пероральные антикоагулянты в структуре тромбопрофилактики на фоне рутинного использования транексамовой кислоты при эндопротезировании тазобедренного сустава. Анестезиология и реаниматология. 2014;59(6):34–38.; Almegren MO, Alhedaithy AA, Alomri AS, Albawardy NF, Mesmar RS, Al Qahtani MA. Venous thromboembolism after total knee and hip arthroplasty. A retrospective study. Saudi Med J. 2018;39(11):1096– 1101. https://doi.org/10.15537/smj.2018.11.23545 PMID: 30397708; Moorhouse A, Giddins G. National variation between clinical commissioning groups in referral criteria for primary total hip replacement surgery. Ann R Coll Surg Engl. 2018;100(6):443–445. https://doi.org/10.1308/rcsann.2018.0044 PMID: 29962296; Santana DC, Emara AK, Orr MN, Klika AK, Higuera CA, Krebs VE, et al. An Update on Venous Thromboembolism Rates and Prophylaxis in Hip and Knee Arthroplasty in 2020. Medicina (Kaunas). 2020;56(9):416. https://doi.org/10.3390/medicina56090416 PMID: 32824931; Каплунов О.А., Михин И.В., Бирюков С.Н. Баланс методов гемостаза и антикоагулянтной терапии при эндопротезировании тазобедренного сустава. Хирургия. Журнал им. Н.И. Пирогова. 2016;(6):77–82. https://doi.org/10.17116/hirurgia2016677-82; Сычев Д.А., Синицина И.И., Цомая И.В., Варданян А.В., Леванов А.Н. Клинико-фармакологическое и клиническое обоснование кратности применения новых пероральных антикоагулянтов. Кардиология. 2017;57(11):84–93. https://doi.org/10087/cardio.2017.11.10058; Борисова Л.В., Николаев Н.С., Пчелова Н.Н., Любимов Е.А. Кровотечение и тромбоз: дисбаланс гемостаза как предиктор развития инфекционных осложнений после протезирования крупных суставов (клинический случай). Кафедра травматологии и ортопедии. 2019;1(35):5–10. https://doi.org/10.17238/issn2226-2016.2019.1.5-10; Мясоедов А.А., Торопов С.С., Березин Г.В., Карелкин В.В., Тотоев З.А., Шубняков И.И. и др. Факторы риска развития перипротезной инфекции после первичного эндопротезирования тазобедренного сустава. Травматология и ортопедия России. 2020;26(1):40–47. https://doi.org/10.21823/2311-2905-2020-26-1-40-47; Сафаров Д.М. Осложнения при эндопротезировании тазобедренного сустава. Вестник Авиценны. 2017;19(4):528–531. https://doi.org/10.25005/2074-0581-2017-19-4-528-531; Антропова И.П., Юшков Б.Г. Особенности реакции системы гемостаза на крупное ортопедическое хирургическое вмешательство. Вестник уральской медицинской академической науки. 2010;4(32):52–56.; Бокерия Л.А., Затевахин И.И., Кириенко А.И., Андрияшкин А.В., Андрияшкин В.В., Арутюнов Г.П. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015;9(4– 2):1–52.; Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70. https://doi.org/10.7326/0003-4819-130-6-199903160-00002. PMID: 10075613; Головко Л.С., Сафроненко А.В., Ганцгорн Е.В. Тромбозы и кровотечения после эндопротезирования крупных суставов нижних конечностей: что может повышать риски развития тромбогеморрагических осложнений? Южно-Российский журнал терапевтической практики. 2020;1(3):75–83. https://doi.org/10.21886/2712-8156-2020-1-3-75-83; Краснова Н.М., Венгеровский А.И., Александрова Т.Н. Коморбидные состояния у пожилых пациентов травматолого-ортопедического профиля. Вестник Северо-Восточного федерального университета им. М.К. Аммосова. Серия: Медицинские науки. 2019;2(15):48– 56. https://doi.org/10.25587/SVFU.2019.2(15).31312; Касимова А.Р., Божкова С.А., Тихилов Р.М., Сараев А.В., Петухов А.И., Журавков А.А. и др. Влияние фармакологической тромбопрофилактики, турникета и дренирования на геморрагические осложнения в ранние сроки после эндопротезирования коленного сустава: предварительные результаты. Травматология и ортопедия России. 2019;25(3):70–80. https://doi.org/10.21823/2311-2905-2019-25-3-70-80; Newman JM, Abola MV, Macpherson A, Klika AK, Barsoum WK, Higuera CA. ABO Blood Group Is a Predictor for the Development of Venous Thromboembolism After Total Joint Arthroplasty. J Arthroplasty. 2017;32(9S):254–258. https://doi.org/10.1016/j.arth.2017.02.063 PMID: 28366316; https://www.jnmp.ru/jour/article/view/1669

Dostupnost: https://www.jnmp.ru/jour/article/view/1669
https://doi.org/10.23934/2223-9022-2023-12-3-369-375

View record from BASE

Nájsť tento článok vo Web of Science

14

Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants ; Современные возможности использования лабораторных методов контроля эффективности и безопасности применения прямых пероральных антикоагулянтов

Autoři: S. R. Gilyarevsky N. K. Vereina M. V. Golshmid a další

Zdroj: Rational Pharmacotherapy in Cardiology; Vol 19, No 3 (2023); 290-297 ; Рациональная Фармакотерапия в Кардиологии; Vol 19, No 3 (2023); 290-297 ; 2225-3653 ; 1819-6446

Témata: дабигатран, blood concentration of anticoagulants, atrial fibrillation, apixaban, rivaroxaban, dabigatran, концентрация антикоагулянтов в крови, фибрилляция предсердий, апиксабан, ривароксабан

Popis souboru: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2922/2430; Chan N, Sager PT, Lawrence J, et al. Is there a role for pharmacokinetic/ phar macodynamic-guided dosing for novel oral anticoagulants? Am Heart J. 2018;199:59-67. DOI:10.1016/j.ahj.2017.10.002.; Chan NC, Eikelboom JW, Weitz JI. Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. Circ Res. 2016;118(9):14091424. DOI:10.1161/CIRCRESAHA.116.306925.; Lee JJ, Ha ACT, Dorian P, Verma M, et al. Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation. Am J Cardiol. 2021;140:62-68. DOI:10.1016/j.amjcard.2020.10.064.; Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2018;118(3):437-450. DOI:10.1055/s-0038-1627480.; Douxfils J, Ageno W, Samama CM, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16(02):209-219. DOI:10.1111/jth.13912.; Toorop MMA, Lijfering WM, Scheres LJJ. The relationship between DOAC levels and clinical outcomes: The measures tell the tale. J Thromb Haemost. 2020;18(12):3163-3168. DOI:10.1111/jth.15104.; Douxfils J, Mullier F, Dogné JM. Dose tailoring of dabigatran etexilate: obvious or excessive? Expert Opin Drug Saf. 2015;14(8):1283-1289. DOI:10.1517/14740338.2015.1049995.; Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016;5(05):e003432. DOI:10.1161/JAHA.116.003432.; Buckley LF, Rybak E, Aldemerdash A, et al. Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. Clin Cardiol. 2017;40(01):46-52. DOI:10.1002/clc.22591.; Chan KE, Giugliano RP, Patel MR, et al. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol. 2016;67(24):2888-2899. DOI:10.1016/j.jacc.2016.02.082.; Levy JH, Ageno W, Chan NC, et al.; Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(03):623-627. DOI:10.1111/jth.13227.; Lindhoff-Last E. Direct oral anticoagulants (DOAC) — Management of emergency situations. Hamostaseologie. 2017;37(4):257-266. DOI:10.5482/HAMO-16-11-0043.; Gendron N, Gay J, Lemoine M, et al. Usefulness of initial plasma dabigatran concentration to predict rebound after reversal. Haematologica. 2018; 103(05):e226-e229. DOI:10.3324/haematol.2017.183400.; Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):13301393. DOI:10.1093/eurheartj/ehy136.; Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply. J Thromb Haemost. 2016;14(12):25592561. DOI:10.1111/jth.13513.; Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures. J Thromb Haemost. 2016;14(7):1325-1327. DOI:10.1111/jth.13344.; Tripodi A, Marongiu F, Moia M, et al. The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. Intern Emerg Med. 2018;13(7):1029-1036. DOI:10.1007/s11739-018-1854-6.; Albaladejo P, Bonhomme F, Blais N, et al. Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) — September 2015. Anaesth Crit Care Pain Med. 2017;36(1):73-76. DOI:10.1016/j.accpm.2016.09.002.; Rimsans J, Douxfils J, Smythe MA, Gosselin RC. Overview and Practical Application of Coagulation Assays in Managing Anticoagulation with Direct Oral Anticoagulants (DOACs). Curr Pharmacol Rep. 2020;6:241-259. DOI:10.1007/s40495-020-00232-7.; Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med. 2019;179(11):1469-1478. DOI:10.1001/jamainternmed.2019.2431.; Shaw JR, Li N, Vanassche T, Coppens M, et al. Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Adv. 2020;4(15):3520-3527. DOI:10.1182/bloodadvances.2020002335.; Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308-1313. DOI:10.1111/jth.13323.; Moll S, Crona DJ, Martin K. Direct oral anticoagulants in extremely obese patients: OK to use? Res Pract Thromb Haemost. 2018;3(2):152-155. DOI:10.1002/rth2.12178.; Jamieson MJ, Byon W, Dettloff RW, et al. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022;22(6):615-631. DOI:10.1007/s40256-022-00524-x.; Testa S, Legnani C, Antonucci E, et al. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost. 2019;17(7):1064-1072. DOI:10.1111/jth.14457.; Testa S, Paoletti O, Legnani C, et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost. 2018;16(5):842-848. DOI:10.1111/jth.14001.; Salmonson T, Dogné JM, Janssen H, et al. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc Pharmacother. 2017;3:(1):42-47. DOI:10.1093/ehjcvp/pvw032.; Meinel TR, Wilson D, Gensicke H, et al.; DOAC-IVT Writing Group for the International DOAC-IVT, TRISP, and CRCS-K-NIH Collaboration. Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants. JAMA Neurol. 2023;80(3):233-243. DOI:10.1001/jamaneurol.2022.4782. Erratum in: JAMA Neurol. 2023;80(4):422.; Willmann S, Thelen K, Kubitza D, et al. Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study. Thromb J. 2018;16:32. DOI:10.1186/s12959-018-0185-1.; Rahman M, George C, Monagle P. Hot topics in coagulation testing: Important considerations for testing children for bleeding/thrombotic disorders. Int J Lab Hematol. 2020;42(1):68-74. DOI:10.1111/ijlh.13198.; Sarode R. Direct oral anticoagulant monitoring: what laboratory tests are available to guide us? Hematology Am Soc Hematol Educ Program. 2019;2019(1):194–197. DOI:10.1182/hematology.2019000027.; Douxfils J, Adcock DM, Bates SM, Favaloro EJ, et al. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2021;121(8):1008-1020. DOI:10.1055/a-1450-8178.; Tarn D, Shih K, Tseng C, et al. Reasons for Nonadherence to the Direct Oral Anticoagulant Apixaban: A Cross-Sectional Survey of Atrial Fibrillation Patients. JACC Adv. 2023;2(1):100175. DOI:10.1016/j.jacadv.2022.100175.; Samoš M, Bolek T, Stančiaková L, et al. Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation? J Clin Med. 2022;11(21):6369. DOI:10.3390/jcm11216369.; Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321-328. DOI:10.1016/j.jacc.2013.07.104.; Sakaguchi T, Osanai H, Murase Y, et al. Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. J Cardiol. 2017;70(3):244-249. DOI:10.1016/j.jjcc.2016.11.013.; Gao H, Li Y, Sun H, et al. Trough Concentration Deficiency of Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events. J Cardiovasc Pharmacol. 2022;80(6):869-876. DOI:10.1097/FJC.0000000000001360.; Sin CF, Wong KP, Wong HM, et al. Plasma Rivaroxaban Level in Patients With Early Stages of Chronic Kidney Disease-Relationships With Renal Function and Clinical Events. Front Pharmacol. 2022;13:888660. DOI:10.3389/fphar.2022.888660.; Škorňová I, Samoš M, Bolek T, et al. Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study. J Cardiovasc Pharmacol. 2021;78(1):e122-e127. DOI:10.1097/FJC.0000000000001038.; Nosáľ V, Petrovičová A, Škorňová I, et al. Plasma levels of direct oral anticoagu- lants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study. Eur J Clin Pharmacol. 2022;78(4):557-564. DOI:10.1007/s00228-022-03280-8.; Favaloro EJ, Pasalic L, Curnow J, Lippi G. Laboratory Monitoring or Measure - ment of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges. Curr Drug Metab. 2017;18(7):598-608. DOI:10.2174/1389200218666170417124035.; Yates SG, Smith S, Tharpe W, et al. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban? Transfus Apher Sci. 2016;55(2):212-215. DOI:10.1016/j.transci.2016.06.005.; Sabor L, Raphaël M, Dogné JM, et al. Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels. Thromb Res. 2017;156:36-38. DOI:10.1016/j.thromres.2017.05.024.; Margetić S, Ćelap I, Delić Brkljačić D, et al. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. Biochem Med (Zagreb). 2020;30(1):010702. doi:10.11613/BM.2020.010702.; Sairaku A, Nakano Y, Onohara Y, et al. Residual anticoagulation activity in atrial fibrillation patients with temporary interrupted direct oral anticoagulants: Comparisons across 4 drugs. Thromb Res. 2019;183:119-123. DOI:10.1016/j.thromres.2019.10.006.; Artang R, Dias JD, Walsh M, et al. Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography. TH Open. 2021;5(4):e570-e576. DOI:10.1055/a-1692-1415.; Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388(10055):2015-2022. DOI:10.1016/S01406736(16)31323-X.; https://www.rpcardio.com/jour/article/view/2922

Dostupnost: https://www.rpcardio.com/jour/article/view/2922
https://doi.org/10.20996/1819-6446-2023-2922

View record from BASE

Nájsť tento článok vo Web of Science

15

Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis ; Влияние носительства гена ABCB1 и межлекарственных взаимодействий на фармакокинетику апиксабана и ривароксабана и клинические исходы у пациентов с фибрилляцией предсердий и тромбозом глубоких вен

Autoři: L. V. Fedina I. N. Sychev T. D. Rastvorova a další

Přispěvatelé: L. V. Fedina I. N. Sychev T. D. Rastvorova a další

Zdroj: Rational Pharmacotherapy in Cardiology; Vol 18, No 6 (2022); 624-629 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 6 (2022); 624-629 ; 2225-3653 ; 1819-6446

Témata: ривароксабан, pharmacogenetics, ABCB1, drug interactions, apixaban, rivaroxaban, фармакогенетика, межлекарственные взаимодействия, апиксабан

Popis souboru: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2848/2375; Kruger PC, Eikelboom JW, Douketis JD, et al. Deep vein thrombosis: update on diagnosis and management. Med J Aust. 2019;210(11):516-24. DOI:10.5694/mja2.50201.; Brighton T. New oral anticoagulant drugs - mechanisms of action. Aust Prescr. 2010;33:38-41. DOI:10.18773/austprescr.2010.017.; Benamouzig R, Guenoun M, Deutsch D, et al. Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants. Cardiovasc Drugs Ther. 2022;36(5):973-89. DOI:10.1007/s10557-021-07211-0; Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272-74. DOI:10.1056/NEJMp1302834.; Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. DOI:10.1056/NEJMoa1310907.; Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018;49(12):2933-44. DOI:10.1161/STROKEAHA.118.020232.; Overvad TF, Larsen TB, Albertsen IE, et al. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2013;11(12):1619-29. DOI:10.1586/14779072.2013.839214.; Скрипка А.И., Когай В.В., Листратов А.И. и др. Персонализированный подход к назначению прямых оральных антикоагулянтов: от теории к практике. Тер Архив. 2019;91(7):111-20. DOI:10.26442/00403660.2019.07.000045.; Byon W, Garonzik S, Boyd RA, et al. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019;58(10):1265-79. DOI:10.1007/s40262-019-00775-z.; Wiggins BS, Dixon DL, Neyens RR, et al. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75(11):1341-50. DOI:10.1016/j.jacc.2019.12.068.; PharmGKB [cited 2022 Oct 13]. Available from: https://www.pharmgkb.org/.; Online Calculator of Hardy-Weinberg equilibrium. WpCalc. [cited 2022 Oct 2]. Available from: https://wpcalc.com/en/equilibrium-hardy-weinberg/.; Raymond J, Imbert L, Cousin T, et al. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. J Pers Med. 2021;11(1):37. DOI:10.3390/jpm11010037.; Xie Q, Xiang Q, Mu G, et al. Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis. Curr Pharm Des. 2018;24(30):3558-65. DOI:10.2174/1381612824666181018153641.; Gouin-Thibault I, Delavenne X, Blanchard A, et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15(2):273-83. DOI:10.1111/jth.13577.; Sychev D, Minnigulov R, Bochkov P, et al. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery. High Blood Press Cardiovasc Prev. 2019;26(5):413-20. DOI:10.1007/s40292-019-00342-4.; Sychev D, Ostroumova O, Cherniaeva M, et al. The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation. High Blood Press Cardiovasc Prev. 2022;29(5):469-80. DOI:10.1007/s40292-022-00536-3.; Dimatteo C, D’Andrea G, Vecchione G, et al. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thromb Res. 2016;145:24-6. DOI:10.1016/j.thromres.2016.07.005.; Kryukov AV, Sychev DA, Andreev DA, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018;11:43-9. DOI:10.2147/PGPM.S157111.; Terrier J, Gaspar F, Fontana P, et al. Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians. Am J Med. 2021;134(8):939-42. DOI:10.1016/j.amjmed.2021.04.003.; Vakkalagadda B, Frost C, Byon W, et al. Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016;16(2):119-27. DOI:10.1007/s40256-015-0157-9.; Frost CE, Byon W, Song Y, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015;79(5):838-46. DOI:10.1111/bcp.12541.; Mikus G, Foerster KI, Schaumaeker M, et al. Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs. Br J Clin Pharmacol. 2020;86(8):1632-41. DOI:10.1111/bcp.14277.; Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66. DOI:10.1111/bcp.12075.; Bartlett JW, Renner E, Mouland E, et al. Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem. Ann Pharmacother. 2019;53(1):21-7. DOI:10.1177/1060028018795140.; Pham P, Schmidt S, Lesko L, et al. Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. JAMA Netw Open. 2020;3(4):e203593. DOI:10.1001/jamanetworkopen.2020.3593.; Mar PL, Gopinathannair R, Gengler BE, et al. Drug Interactions Affecting Oral Anticoagulant Use. Circ Arrhythm Electrophysiol. 2022;15(6):e007956. DOI:10.1161/CIRCEP.121.007956.; https://www.rpcardio.com/jour/article/view/2848

Dostupnost: https://www.rpcardio.com/jour/article/view/2848
https://doi.org/10.20996/1819-6446-2022-12-02

View record from BASE

Nájsť tento článok vo Web of Science

16

Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants ; Тромбоз левого желудочка: состояние проблемы и место прямых оральных антикоагулянтов

Autoři: A. D. Aga A. A. Sokolova D. A. Napalkov a další

Zdroj: Rational Pharmacotherapy in Cardiology; Vol 18, No 6 (2022); 727-733 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 6 (2022); 727-733 ; 2225-3653 ; 1819-6446

Témata: кардиомиопатия, warfarin, anticoagulants, left ventricular thrombosis, direct oral anticoagulants, apixaban, rivaroxaban, dabigatran, myocardial infarction, cardiomyopathy, варфарин, антикоагулянты, тромбоз левого желудочка, прямые оральные антикоагулянты, апиксабан, ривароксабан, дабигатран, инфаркт миокарда

Popis souboru: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2862/2388; Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. DOI:10.1093/eurheartj/ehx393.; Кропачева Е.С. Внутрисердечный тромбоз: частота, факторы риска и место пероральных антикоагулянтов в лечении. Атеротромбоз. 2020;(1):134-52. DOI:10.21518/2307-1109-2020-1-134-152.; Habash F, Vallurupalli S. Challenges in management of left ventricular thrombus. Ther Adv Cardiovasc Dis. 2017;11(8):203-13. DOI:10.1177/1753944717711139.; Robinson AA, Jain A, Gentry M, McNamara RL. Left ventricular thrombi after STEMI in the primary PCI era: A systematic review and meta-analysis. Int J Cardiol. 2016;221:554-9. DOI:10.1016/j.ijcard.2016.07.069.; Pöss J, Desch S, Eitel C, et al. Left Ventricular Thrombus Formation After ST-Segment-Elevation Myocardial Infarction: Insights From a Cardiac Magnetic Resonance Multicenter Study. Circ Cardiovasc Imaging. 2015;8(10):e003417. DOI:10.1161/CIRCIMAGING.115.003417.; Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction. Heart. 2012;98(23):1743-9. DOI:10.1136/heartjnl-2012-301962.; Roifman I, Connelly KA, Wright GA, Wijeysundera HC. Echocardiography vs. Cardiac Magnetic Resonance Imaging for the Diagnosis of Left Ventricular Thrombus: A Systematic Review. Can J Cardiol. 2015;31(6):785-91. DOI:10.1016/j.cjca.2015.01.011.; Weinsaft JW, Kim J, Medicherla CB, et al. A Novel Imaging Algorithm for Post Myocardial Infarction Left Ventricular Thrombus – Regional LV Function on Echocardiography as a Gatekeeper for Thrombus Evaluation by Delayed Enhancement Cardiac Magnetic Resonance. JACC Cardiovasc Imaging. 2016;9(5):505-15. DOI:10.1016/j.jcmg.2015.06.017.; Dinesh Kumar US, Shetty SP, Sujay KR, Wali M. Left ventricular mass: A tumor or a thrombus diagnostic dilemma. Ann Card Anaesth. 2016;19(4):728-32. DOI:10.4103/0971-9784.191551.; Lemaître AI, Picard F, Maurin V et al. Clinical profile and midterm prognosis of left ventricular thrombus in heart failure. ESC Heart Fail. 2021;8(2):1333-41. DOI:10.1002/ehf2.13211.; Hamada M. Left Ventricular Thrombus in Hypertrophic Cardiomyopathy. Intern Med Tokyo Jpn. 2019;58(4):465-7. DOI:10.2169/internalmedicine.1646-18.; Becker RC, Owens AP, Sadayappan S. Tissue-Level Inflammation and Ventricular Remodeling in Hypertrophic Cardiomyopathy. J Thromb Thrombolysis. 2020;49(2):177-83. DOI:10.1007/s11239-019-02026-1.; Herath HMMTB, Pahalagamage SP, Lindsay LC, et al. Takotsubo cardiomyopathy complicated with apical thrombus formation on first day of the illness: a case report and literature review. BMC Cardiovasc Disord. 2017;17(1):176. DOI:10.1186/s12872-017-0616-0.; Ding KJ, Cammann VL, Szawan KA, et al. Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome: Insights From the International Takotsubo Registry. Arterioscler Thromb Vasc Biol. 2020;40(1):279-87. DOI:10.1161/ATVBAHA.119.313491.; Шилова А.С., Шмоткина А.О., Яфарова А.А., Гиляров М.Ю. Синдром такоцубо: современные представления о патогенезе, распространенности и прогнозе. Рациональная Фармакотерапия В Кардиологии. 2018;14(4):598-604. DOI:10.20996/1819-6446-201814-4-598-604.; Chimenti C, Lavalle C, Magnocavallo M, et al. A proposed strategy for anticoagulation therapy in noncompaction cardiomyopathy. ESC Heart Fail. 2021;9(1):241-50. DOI:10.1002/ehf2.13694.; Pitta S, Thatai D, Afonso L. Thromboembolic complications of left ventricular noncompaction: case report and brief review of the literature. J Clin Ultrasound JCU. 2007;35(8):465-8. DOI:10.1002/jcu.20349.; Bakalli A, Georgievska-Ismail L, Koçinaj D, et al. Left ventricular and left atrial thrombi in sinus rhythm patients with dilated ischemic cardiomyopathy. Med Arch Sarajevo Bosnia Herzeg. 2012;66(3):155-8. DOI:10.5455/medarh.2012.66.155-158.; Chan NC, Weitz JI. COVID-19 coagulopathy, thrombosis, and bleeding. Blood. 2020;136(4):381-3. DOI:10.1182/blood.2020007335.; Giustino G, Pinney SP, Lala A, et al. Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia. J Am Coll Cardiol. 2020;76(17):2011-23. DOI:10.1016/j.jacc.2020.08.059.; Lala A, Johnson KW, Januzzi JL, et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am Coll Cardiol. 2020;76(5):533-46. DOI:10.1016/j.jacc.2020.06.007.; Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543-58. DOI:10.1038/s41569-020-0413-9.; Diaz-Arocutipa C, Torres-Valencia J, Saucedo-Chinchay J, Cuevas C. ST-segment elevation in patients with COVID-19: a systematic review. J Thromb Thrombolysis. 2021;52(3):738-45. DOI:10.1007/s11239-021-02411-9.; Azevedo RB, Botelho BG, Hollanda JVG de, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35(1):4-11. DOI:10.1038/s41371-020-0387-4.; Fenton M, Siddavaram S, Sugihara C, Husain S. Lessons of the month 3: ST-elevation myocardial infarction and left ventricular thrombus formation: an arterial thrombotic complication of severe COVID-19 infection. Clin Med Lond Engl. 2020;20(4):437-9. DOI:10.7861/clinmed.2020-0266.; Materna O, Koubský K, Pádr R, Janoušek J. Major left ventricular thrombi in an adolescent with COVID19-associated inflammatory syndrome. Eur Heart J. 2021;42(33):3207. DOI:10.1093/eurheartj/ehab165.; O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-140. DOI:10.1016/j.jacc.2012.11.019.; Guyatt GH, Akl EA, Crowther M, et al. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S-47S. DOI:10.1378/chest.1412S3.; Abdelnabi M, Saleh Y, Fareed A, et al. Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT Trial). J Am Coll Cardiol. 2021;77(12):1590-2. DOI:10.1016/j.jacc.2021.01.049.; Alcalai R, Butnaru A, Moravsky G, et al. Apixaban versus Warfarin in Patients with Left Ventricular Thrombus, A Prospective Multicenter Randomized Clinical Trial. Eur Heart J Cardiovasc Pharmacother. 2022;8(7):660-7. DOI:10.1093/ehjcvp/pvab057.; Isa W Y W, Hwong N, Mohamed Yusof AK, et al. Apixaban versus Warfarin in Patients with Left Ventricular Thrombus: A Pilot Prospective Randomized Outcome Blinded Study Investigating Size Reduction or Resolution of Left Ventricular Thrombus. J Clin Prev Cardiol. 2020;9(4):150-4. DOI:10.4103/JCPC.JCPC_41_20.; Bass ME, Kiser TH, Page RL, et al. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J Thromb Thrombolysis. 2021;52(2):517-22. DOI:10.1007/s11239-020-02371-6.; Cochran JM, Jia X, Kaczmarek J, et al. Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: A Retrospective, Multicenter Study and Meta-Analysis of Existing Data. J Cardiovasc Pharmacol Ther. 2021;26(2):173-8. DOI:10.1177/1074248420967644.; Daher J, Da Costa A, Hilaire C, et al. Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists. Clin Drug Investig. 2020;40(4):343- 53. DOI:10.1007/s40261-020-00898-3.; Durrer-Ariyakuddy K, Moccetti F, Stämpfli S. Direct oral anticoagulants versus vitamin K antagonists for treatment of left ventricular thrombus – insights from multicenter registry. Cardiovasc Med. 2019;22:P27. DOI:10.4414/cvm.2019.02052.; Gama F, Freitas P, Trabulo M, et al. Direct oral anticoagulants are an effective therapy for left ventricular thrombus formation. Eur Heart J. 2019;40(Suppl_1):ehz747.0118. DOI:10.1093/eurheartj/ehz747.0118.; Guddeti RR, Anwar M, Walters RW, et al. Treatment of Left Ventricular Thrombus With Direct Oral Anticoagulants: A Retrospective Observational Study. Am J Med. 2020;133(12):1488-91. DOI:10.1016/j.amjmed.2020.05.025.; Iqbal H, Straw S, Craven TP, et al. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. ESC Heart Fail. 2020;7(5):2032-41. DOI:10.1002/ehf2.12718.; Jaidka A, Zhu T, Lavi S, Johri A. Treatment of left ventricular thrombus using warfarin versus direct oral anticoagulants following anterior myocardial infarction Can J Cardiol. 2018;34(10):S143. DOI:10.1016/j.cjca.2018.07.194.; Willeford A, Zhu W, Stevens C, Thomas IC. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus. Ann Pharmacother. 2021;55(7):839-45. DOI:10.1177/1060028020975111.; Xu Z, Li X, Li X, et al. Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus. Ann Palliat Med. 2021;10(9):9427-34. DOI:10.21037/apm-21-1683.; Yunis A, Seese L, Stearns B, et al. Direct oral anticoagulants are effective therapy in treating left ventricular thrombi. J Am Coll Cardiol. 2020;75(11):948. DOI:10.1016/S0735-1097(20)31575-8.; Jones DA, Wright P, Alizadeh MA, et al. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):398-404. DOI:10.1093/ehjcvp/pvaa096.; Ali Z, Isom N, Dalia T, et al. Direct oral anticoagulant use in left ventricular thrombus. Thromb J. 2020;18:29. DOI:10.1186/s12959-020-00242-x.; Saleh Y, Al-Abcha A, Abdelkarim O, et al. Meta-Analysis Investigating the Role of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi. Am J Cardiol. 2021;150:126- 8. DOI:10.1016/j.amjcard.2021.03.032.; Saleiro C, Lopes J, De Campos D, et al. Left Ventricular Thrombus Therapy With Direct Oral Anticoagulants Versus Vitamin K Antagonists: A Systematic Review and Meta-Analysis. J Cardiovasc Pharmacol Ther. 2021;26(3):233-43. DOI:10.1177/1074248420977567.; Li S, Deng Y, Tong Y, et al. Assessment of non-vitamin K antagonist oral anticoagulants for the management of left ventricular thrombus. Clin Cardiol. 2021;44(6):754-60. DOI:10.1002/clc.23553.; Michael F, Natt N, Shurrab M. Direct Oral Anticoagulants vs Vitamin K Antagonists in Left Ventricular Thrombi: A Systematic Review and Meta-analysis. CJC Open. 2021;3(9):1169-81. DOI:10.1016/j.cjco.2021.04.007.; Trongtorsak A, Thangjui S, Kewcharoen J, et al. Direct oral anticoagulants vs. vitamin K antagonists for left ventricular thrombus: a systematic review and meta-analysis. Acta Cardiol. 2021;76(9):933-42. DOI:10.1080/00015385.2020.1858538.; Kajy M, Shokr M, Ramappa P. Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: Systematic Review of Current Literature. Am J Ther. 2020;27(6):e584-90. DOI:10.1097/MJT.0000000000000937.; Tomasoni D, Sciatti E, Bonelli A, et al. Direct Oral Anticoagulants for the Treatment of Left Ventricular Thrombus-A New Indication? A Meta-summary of Case Reports. J Cardiovasc Pharmacol. 2020;75(6):530-4. DOI:10.1097/FJC.0000000000000826.; Abdelaziz HK, Megaly M, Debski M, et al. Meta-Analysis Comparing Direct Oral Anticoagulants to Vitamin K Antagonists for The Management of Left Ventricular Thrombus. Expert Rev Cardiovasc Ther. 2021;19(5):427-32. DOI:10.1080/14779072.2021.1915134.; Chen R, Zhou J, Liu C, et al. Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus: a systematic review and meta-analysis. Pol Arch Intern Med. 2021;131(5):429- 38. DOI:10.20452/pamw.15923.; Kido K, Ghaffar YA, Lee JC, et al. Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with left ventricular thrombus. PloS One. 2021;16(6):e0252549. DOI:10.1371/journal.pone.0252549.; Robinson AA, Trankle CR, Eubanks G, et al. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi. JAMA Cardiol. 2020;5(6):685-92. DOI:10.1001/jamacardio.2020.0652.; Lim CW, Mamat RM, Hishammudin IA, et al. Left Ventricular Thrombus: Patient Characteristics and Treatment from a Single Tertiary Centre’s Experience. Int J Cardiol. 2019;297:20-1. DOI:10.1016/j.ijcard.2019.11.056.; Degheim G, Berry A, Zughaib M. Off label use of direct oral anticoagulants for left ventricular thrombus. Is it appropriate? Am J Cardiovasc Dis. 2017;7(5):98-101.; Moey MYY, Tomdio AN, Achike O, Kabirdas D. Large Left Ventricular Thrombus as a Cause of Recurrent Cardioembolic Stroke While on Dabigatran. CASE Cardiovasc Imaging Case Rep. 2018;2(5):222-4. DOI:10.1016/j.case.2018.04.008.; Kaya A, Hayıroğlu Mİ, Keskin M, et al. Resolution of left ventricular thrombus with apixaban in a patient with hypertrophic cardiomyopathy. Turk Kardiyol Dernegi Arsivi Turk Kardiyol Derneginin Yayin Organidir. 2016;44(4):335-7. DOI:10.5543/tkda.2015.68054.; Kaku B. Intra-cardiac thrombus resolution after anti-coagulation therapy with dabigatran in a patient with mid-ventricular obstructive hypertrophic cardiomyopathy: a case report. J Med Case Reports. 2013;7:238. DOI:10.1186/1752-1947-7-238.; Elikowski W, Małek-Elikowska M, Fertała N, et al. Fast apixaban-related resolution of left ventricular thrombi in a patient with dilated cardiomyopathy. Pol Merkur Lek Organ Pol Tow Lek. 2018;44(259): 19-22.; Sun H, Zhao Q, Wang Y, et al. Daily 10 mg rivaroxaban as a therapy for ventricular thrombus related to left ventricular non-compaction cardiomyopathy. Medicine (Baltimore). 2018;97(4):e9670. DOI:10.1097/MD.0000000000009670.; Bahmaid RA, Ammar S, Al-Subaie S, et al. Efficacy of direct oral anticoagulants on the resolution of left ventricular thrombus—A case series and literature review. JRSM Cardiovasc Dis. 2019;8: 2048004019839548. DOI:10.1177/2048004019839548.; Shokr M, Ahmed A, Abubakar H, et al. Use of direct oral anticoagulants in the treatment of left ventricular thrombi: A tertiary center experience and review of the literature. Clin Case Rep. 2018;7(1):135-42. DOI:10.1002/ccr3.1917.; Smetana KS, Dunne J, Parrott K, et al. Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series. J Thromb Thrombolysis. 2017;44(4):519-24. DOI:10.1007/s11239-017-1560-7.; Verma B, Singh A, Kumar M. Use of dabigatran for treatment of left ventricular thrombus: A tertiary care center experience. J Fam Med Prim Care. 2019;8(8):2656-60. DOI:10.4103/jfmpc.jfmpc_459_19.; https://www.rpcardio.com/jour/article/view/2862

Dostupnost: https://www.rpcardio.com/jour/article/view/2862
https://doi.org/10.20996/1819-6446-2022-12-10

View record from BASE

Nájsť tento článok vo Web of Science

17

Need to determine the residual concentrations of direct oral anticoagulants in patients with atrial fibrillation undergoing transcatheter implantation of the aortic valve ; Необходимость определения остаточных концентраций прямых оральных антикоагулянтов у больных фибрилляцией предсердий, подвергнутых транскатетерной имплантации аортального клапана

Autoři: A. I. Staroverova E. S. Kropacheva A. B. Dobrovolsky a další

Zdroj: Aterotromboz = Atherothrombosis; Том 13, № 1 (2023); 46-57 ; Атеротромбоз; Том 13, № 1 (2023); 46-57 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2023-1

Témata: высокий риск кровотечений, anticoagulant withdrawal, coagulation tests, anti-Xa activity, diluted thrombin time, apixaban, rivaroxaban, dabigatran, chronic kidney disease, high bleeding risk, отмена антикоагулянта, коагуляционные тесты, анти-Хаактивность, разведенное тромбиновое время, апиксабан, ривароксабан, дабигатран, хроническая болезнь почек

Popis souboru: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/301/306; Панченко Е.П., Комаров А.Л., Кропачева Е.С., Добровольский А.Б. Протокол ведения пациентов, нуждающихся в длительном приеме антитромботической терапии, при инвазивных вмешательствах. Кардиологический вестник. 2020;(2):63–77. https://doi.org/10.36396/MS.2020.65.42.009.; Steffel J., Verhamme P., Potpara T.S., Albaladejo P., Antz M., Desteghe L. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393. https://doi.org/10.1093/eurheartj/ehy136.; Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.; Douketis J.D., Healey J.S., Brueckmann M., Eikelboom J.W., Ezekowitz M.D., Fraessdorf M. et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015;113(3):625–632. https://doi.org/10.1160/TH14-04-0305.; Beyer-Westendorf J., Gelbricht V., Förster K., Ebertz F., Köhler C., Werth S. et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35(28):1888–1896. https://doi.org/10.1093/eurheartj/eht557.; Nazha B., Pandya B., Cohen J., Zhang M., Lopes R.D., Garcia D.A. et al. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. Circulation. 2018;138(14):1402–1411. https://doi.org/10.1161/CIRCULATIONAHA.117.031457.; Shaw J.R., Li N., Vanassche T., Coppens M., Spyropoulos A.C., Syed S. et al. Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Adv. 2020;4(15):3520–3527. https://doi.org/10.1182/bloodadvances.2020002335.; Piccolo R., Pilgrim T., Franzone A., Valgimigli M., Haynes A., Asami M. et al. Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2017;10(14):1436–1446. https://doi.org/10.1016/j.jcin.2017.04.034.; Dangas G.D., Mehran R. Bleeding After Aortic Valve Replacement Matters: Important Mortality Risk. JACC Cardiovasc Interv. 2017;10(14):1447–1448. https://doi.org/10.1016/j.jcin.2017.06.005.; Wang J., Yu W., Jin Q., Li Y., Liu N., Hou X., Yu Y. Risk Factors for Post-TAVI Bleeding According to the VARC-2 Bleeding Definition and Effect of the Bleeding on Short-Term Mortality: A Meta-analysis. Can J Cardiol. 2017;33(4):525–534. https://doi.org/10.1016/j.cjca.2016.12.001.; Godier A., Dincq A.S., Martin A.C., Radu A., Leblanc I., Antona M. et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J. 2017;38(31):2431–2439. https://doi.org/10.1093/eurheartj/ehx403.; Fox V., Kleikamp A., Dittrich M., Zittermann A., Flieder T., Knabbe C. et al. Direct oral anticoagulants and cardiac surgery: A descriptive study of preoperative management and postoperative outcomes. J Thorac Cardiovasc Surg. 2021;161(5):1864–1874.e2. https://doi.org/10.1016/j.jtcvs.2019.11.119.; Reilly P.A., Lehr T., Haertter S., Connolly S.J., Yusuf S., Eikelboom J.W. et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321–328. https://doi.org/10.1016/j.jacc.2013.07.104.; Cirincione B., Kowalski K., Nielsen J., Roy A., Thanneer N., Byon W. et al. Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation. CPT Pharmacometrics Syst Pharmacol. 2018;7(11):728–738. https://doi.org/10.1002/psp4.12347.; Schellings M.W., Boonen K., Schmitz E.M., Jonkers F., van den Heuvel D.J., Besselaar A. et al. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. Thromb Res. 2016;139:128–134. https://doi.org/10.1016/j.thromres.2016.01.012.; Титаева Е.В., Добровольский А.Б. Хромогенный антиХа-тест: соотношение между единицами активности гепарина и концентрацией апиксабана и ривароксабана. Атеротромбоз. 2020;(2):96–104. https://doi.org/10.21518/2307-1109-2020-2-96-104.; Spyropoulos A.C., Brohi K., Caprini J., Samama C.M., Siegal D., Tafur A. et al. Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. J Thromb Haemost. 2019;17(11):1966–1972. https://doi.org/10.1111/jth.14598.; Godier A., Fontana P., Motte S., Steib A., Bonhomme F., Schlumberger S. et al. Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). Anaesth Crit Care Pain Med. 2018;37(4):379–389. https://doi.org/10.1016/j.accpm.2017.12.012.; Erdoes G., Wouters P.F., Alston R.P., Schreiber J.U., Bettex D., Antoniou T. et al. European Association of Cardiothoracic Anesthesiology and Intensive Care (EACTAIC) Fellowship Curriculum: Second Edition. J Cardiothorac Vasc Anesth. 2022;36(9):3483–3500. https://doi.org/10.1053/j.jvca.2022.05.022.; https://www.aterotromboz.ru/jour/article/view/301

Dostupnost: https://www.aterotromboz.ru/jour/article/view/301
https://doi.org/10.21518/at2023-008

View record from BASE

Nájsť tento článok vo Web of Science

18

Safety of discontinuation of anticoagulants after venous thromboembolism: whether D-dimer level should be taken into account? ; Безопасная отмена антикоагулянтов после венозных тромбоэмболических осложнений: стоит ли ориентироваться на концентрацию D-димера в крови?

Autoři: I. S. Yavelov И. С. Явелов The work was carried out within the framework of the state task “The choice of the optimal method for the treatment of acute ascending varicothrombophlebitis of the veins of the lower extremities: comparison of the results of endovenous laser obliteration of the great saphenous vein and conservative therapy”, registration No. 121021100116-2. a další

Přispěvatelé: I. S. Yavelov И. С. Явелов The work was carried out within the framework of the state task “The choice of the optimal method for the treatment of acute ascending varicothrombophlebitis of the veins of the lower extremities: comparison of the results of endovenous laser obliteration of the great saphenous vein and conservative therapy”, registration No. 121021100116-2. a další

Zdroj: Aterotromboz = Atherothrombosis; Том 12, № 2 (2022); 22-31 ; Атеротромбоз; Том 12, № 2 (2022); 22-31 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2022-2

Témata: тромбоз глубоких вен, тромбоэмболия легочных артерий, D-димер, антикоагулянты, апиксабан, pulmonary embolism, D-dimer, anticoagulants, apixaban

Popis souboru: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/284/297; Бокерия Л.А., Затевахин И.И., Кириенко А.И., Андрияшкин А.В., Андрияшкин В.В., Арутюнов Г.П. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015;9(4-2):1–51. Режим доступа: https://webmed.irkutsk.ru/doc/pdf/pe2015.pdf.; Konstantinides S.V., Meyer G., Becattini C., Bueno H., Geersing G.J., Harjola V.P. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405.; Ortel T.L., Neumann I., Ageno W., Beyth R., Clark N.P., Cuker A. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738. https://doi.org/10.1182/bloodadvances.2020001830.; Stevens S.M., Woller S.C., Kreuziger L.B., Bounameaux H., Doerschug K., Geersing G.J. et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021; 160(6):e545–e608. https://doi.org/10.1016/j.chest.2021.07.055.; Mazzolai L., Ageno W., Alatri A., Bauersachs R., Becattini C., Brodmann M. et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. Eur J Prev Cardiol. 2022;29(8):1248–1263. https://doi.org/10.1093/eurjpc/zwab088.; Kakkos S.K., Gohel M., Baekgaard N., Bauersachs R., Bellmunt-Montoya S., Black S.A. et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. 2021;61(1):9–82. https://doi.org/10.1016/j.ejvs.2020.09.023.; Prins M.H., Lensing A.W.A., Prandoni P., Wells P.S., Verhamme P., Beyer-Westendorf J. et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv. 2018;2(7):788–796. https://doi.org/10.1182/bloodadvances.2018017160.; Palareti G., Cosmi B., Legnani C., Tosetto A., Brusi C., Iorio A. et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355(17):1780–1789. https://doi.org/10.1056/NEJMoa054444.; Cosmi B., Legnani C., Tosetto A., Pengo V., Ghirarduzzi A., Testa S. et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood. 2010;115(3):481–488. https://doi.org/10.1182/blood-2009-08-237354.; Rodger M.A., Le Gal G., Anderson D.R., Schmidt J., Pernod G., Kahn S.R. et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017;356:j1065. https://doi.org/10.1136/bmj.j1065.; Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M. et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708. https://doi.org/10.1056/NEJMoa1207541.; Palareti G., Poli D., Ageno W., Legnani C., Antonucci E., Bucherini E. et al. D-dimer and reduced dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study. Blood Adv. 2022:bloodadvances.2022007973. https://doi.org/10.1182/bloodadvances.2022007973.; Стойко Ю.М., Кириенко А.И., Илюхин Е.А., Лобастов К.В., Чаббаров Р.Г., Париков М.А. и др. Диагностика и лечение тромбофлебита поверхностных вен конечностей. Рекомендации Ассоциации флебологов России. Флебология. 2019;13(2):78–97. https://doi.org/10.17116/flebo20191302178.; Decousus H., Prandoni P., Mismetti P., Bauersachs R.M., Boda Z., Brenner B. et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med. 2010;363(13):1222–1232. https://doi.org/10.1056/NEJMoa0912072.; Cosmi B., Filippini M., Tonti D., Avruscio G., Ghirarduzzi A., Bucherini E. et al. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost. 2012;10(6):1026–1235. https://doi.org/10.1111/j.1538-7836.2012.04727.x.; Beyer-Westendorf J., Schellong S.M., Gerlach H., Rabe E., Weitz J.I., Jersemann K. et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017;4(3):e105–e113. https://doi.org/10.1016/S2352-3026(17)30014-5.; https://www.aterotromboz.ru/jour/article/view/284

Dostupnost: https://www.aterotromboz.ru/jour/article/view/284
https://doi.org/10.21518/2307-1109-2022-12-2

View record from BASE

Nájsť tento článok vo Web of Science

19

Personalization of Anticoagulant Therapy with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease Based on Pharmacogenetic Testing ; Персонализация антикоагулянтной терапии прямыми оральными антикоагулянтами у пациентов с фибрилляцией предсердий и хронической болезнью почек на основе фармакогенетического тестирования

Autoři: Sychev D.A. Batyukina S.V. Ostroumova O.D. a další

Přispěvatelé: Sychev D.A. Batyukina S.V. Ostroumova O.D. a další

Zdroj: Annals of the Russian academy of medical sciences; Vol 78, No 2 (2023); 120-131 ; Вестник Российской академии медицинских наук; Vol 78, No 2 (2023); 120-131 ; 2414-3545 ; 0869-6047 ; 10.15690/vramn.782

Témata: atrial fibrillation, chronic kidney disease, anticoagulants, apixaban, pharmacogenetics, bleeding, personalized medicine, ABCB1, CYP3A4, CYP3A5, фибрилляция предсердий, хроническая болезнь почек, антикоагулянты, апиксабан, фармакогенетика, фармакокинетика, кровотечения, персонализированная медицина

Popis souboru: application/pdf

Relation: https://vestnikramn.spr-journal.ru/jour/article/view/7807/1785; https://vestnikramn.spr-journal.ru/jour/article/view/7807/1788; https://vestnikramn.spr-journal.ru/jour/article/view/7807/1801; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/7807/50780

Dostupnost: https://vestnikramn.spr-journal.ru/jour/article/view/7807
https://doi.org/10.15690/vramn7807

View record from BASE

Nájsť tento článok vo Web of Science

20

Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review ; Тромбоцитопения, индуцируемая прямыми пероральными антикоагулянтами: клинический случай и обзор литературы

Autoři: B. A. Tatarsky N. V. Kazennova Б. А. Татарский a další

Zdroj: Rational Pharmacotherapy in Cardiology; Vol 18, No 5 (2022); 600-605 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 5 (2022); 600-605 ; 2225-3653 ; 1819-6446

Témata: апиксабан, atrial fibrillation, dabigatran, rivaroxaban, apixaban, фибрилляция предсердий, дабигатран, ривароксабан

Popis souboru: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2829/2367; Ghoshal K., Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Scientific World Journal 2014; 2014:781857.DOI:10.1155/2014/781857; Koupenova M., Clancy L., Corkrey H., et al. Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis. Circ Res. 2018;122:337-351.DOI:10.1161/ CIRCRESAHA. 117.310795; Connolly S., Ezekowitz M., Yusuf S., et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361:1139-1151. DOI:10.1056/NEJMoa0905561.; Patel M., Mahaffey K., Garg J., et al. Rivaroxaban versus Warfarin in Nonval-vular Atrial Fibrillation. N Engl J Med 2011;365:883-891. DOI:10.1056/NEJMoa1009638; Granger C., Alexander J., McMurray J., et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011;365:981-992. DOI:10.1056/NEJMoa1107039; Park J., Cha M.J., Choi Y.J., et al. Prognostic efficacy of platelet count in patients with nonvalvular atrial fibrillation. Heart Rhythm 2019;16:197-203. DOI:10.1016/j.hrthm.2018.08.023; George J.N., Aster R.H. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology (Am Soc Hematol Educ Program). 2009:153-158. DOI:10.1182/asheducation-2009.1.153; AL-Nouri Z.I., George J.N. Drug-induced thrombocytopenia. An updated systematic review, 2012. Drug Saf 2012;35:693-4. DOI:10.2165/11633310-000000000-00000; Bonaccio M., Di Castelnuovo A., Costanzo S., et al. Age- and sex-based ranges of platelet count and causespecific mortality risk in an adult general population: prospective findings from the Moli-sani study. Platelets. 2018;29:312-315 DOI: 0.1080/09537104.2017.1411584; Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) European Heart Journal 2020 Doi:10.1093/eurheartj/ehaa612; Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2015;373(3):252-261. DOI:10.1056/NEJMcp1411910; Erdem G.U., Dogan M., Demirci N.S., et al. Oxaliplatin-induced acute thrombocytopenia. J Cancer Res Ther. 2016;12(2):509-514. DOI:10.4103/0973-1482.154056.; Fountain E.M., Arepally G.M. Etiology and complications of thrombocytopenia in hospitalized medical patients. J Thromb Thrombolysis. 2017;43:429-436 DOI:10.1007/s11239-016-1467-8; Mc Carthty С., Steg P., Bhatt D. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur Heart J. 2017; 38: 3488-3492 DOI:10.1093/eurheartj/ehx531; Yadav M., Genereux P., Giustino G., et al. Effect of baseline thrombocytopenia on ischemic outcomes in patients with acute coronary syndromes who undergo percutaneous coronary intervention. Can J Cardiol. 2016;32:226-233. DOI:10.1016/j.cjca.2015.05.020; Janion-Sadowska A., Papuga-Szela E., Łukaszuk R., et al. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia. Cardiovasc Pharmacol. 2018 Sep;72(3):153-160. DOI:10.1097/FJC.0000000000000607; Pastori D., Antonucci E., Violi.F., et al. Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. Journal of the American Heart Association. 2019;8(21):e012596. DOI 10.1161/JAHA.119.012596.; Michowitz Y., Klempfner R., Shlomo N., et al. Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy. 2019. PLOS ONE 14(11): e0224709. DOI:10.1371/journal.pone.0224709; Kalabalik J., Rattinger G., Sullivan J., et al. Use of nonvitamin K antagonist oral anticoagulants in special patient populations with nonvalvular atrial fibrillation: a review of the literature and application to clinical practice. Drugs 2015;75:979-998. DOI:10.1007/s40265-015-0405-y; Deidda A., Rapallo M., Sofia M., et al. Thrombocytopenia possibly induced by dabigatran: a case report. Aust J Pharm. 2015;3:1000170. DOI:10.4172/2329-6887.1000170; Naranjo С.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther., 1981;30:239-45 DOI:10.1038/clpt.1981.154; Kang H.G., Lee S.J., Chung J.Y., et al. BMC Neurology 2017; 17:124-129 DOI:10.1186/s12883-017-0900-8; U.S. Food and Drug Administration. 2018. Potential Signals of Serious Risks/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS): fda.gov/drugs/questions-and-answersfdas-adverse-event-reporting-system-faers/july-september-2017-potential-signals-serious-risksnew-safe ty-information-identified-fda-adverse.; Mima Y., Sangatsuda Y., Yasaka M., et al. Acute thrombocytopenia after initiating anticoagulation with rivaroxaban Intern Med. 2014;53(21):2523-7. DOI:10.2169/internalmedicine.53.2890; He X.Y., Bai Y. Acute thrombocytopenia after anticoagulation with rivaroxaban: A case report. World J Clin Cases. 2020;8(5):928-931. DOI:10.12998/wjcc.v8.i5.928.; ELIQUIS (apixaban). Product Monograph. ELIQUIS (apixaban). 2019. Montreal, Canada H4S 0A4 www.bmscanada.ca; Snellgrove O. Case report: apixaban-induced thrombocytopenia. Clinical Case Reports 2017; 5(3): 268-269 DOI:10.1002/ccr3.809; Sadaka S. Thrombocytopenia: A possible side effect of apixaban. Clin Case Rep. 2019;7:2543-2544 DOI:10.1002/ccr3.2532; https://www.rpcardio.com/jour/article/view/2829

Dostupnost: https://www.rpcardio.com/jour/article/view/2829
https://doi.org/10.20996/1819-6446-2022-10-06

View record from BASE

Nájsť tento článok vo Web of Science

Výsledky vyhledávání - "апиксабан"

Vyhledávací nástroje:

Upřesnit hledání

Médium

Téma

Vydavatel

Vydáno v

Zdroj

Sbírka

Rok vydání